



This is a repository copy of *Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia: a systematic review and meta-analysis.*

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/203048/>

Version: Accepted Version

Article:

Karakonstantis, S. orcid.org/0000-0002-2643-3184, Rousaki, M., Vassilopoulou, L. et al. (1 more author) (2024) Global prevalence of cefiderocol non-susceptibility in Enterobacterales, *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Stenotrophomonas maltophilia*: a systematic review and meta-analysis. *Clinical Microbiology and Infection*, 30 (2). pp. 178-188. ISSN 1198-743X

<https://doi.org/10.1016/j.cmi.2023.08.029>

© 2023 The Authors. Except as otherwise noted, this author-accepted version of a journal article published in *Clinical Microbiology and Infection* is made available via the University of Sheffield Research Publications and Copyright Policy under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

1 **Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas**
2 **aeruginosa, Acinetobacter baumannii and Stenotrophomonas maltophilia: a systematic**
3 **review and meta-analysis**

4 Stamatis KARAKONSTANTIS ¹, Maria ROUSAKI ², Loukia VASSILOPOULOU ³, Evangelos I.
5 KRITSOTAKIS ^{4,5} *

6

7 Affiliations:

8 ¹ Internal Medicine Department, Infectious Diseases Division, University Hospital of Heraklion, Crete,
9 Greece

10 ² Master of Public Health Program, Department of Social Medicine, School of Medicine, University of
11 Crete, Heraklion, Crete, Greece

12 ³ 2nd Department of Internal Medicine, Venizeleio-Pananeio General Hospital, Heraklion, Crete,
13 Greece

14 ⁴ Laboratory of Biostatistics, Department of Social Medicine, School of Medicine, University of Crete,
15 Heraklion, Crete, Greece

16 ⁵ School of Health and Related Research, Faculty of Medicine, Dentistry and Health, University of
17 Sheffield, Sheffield, UK.

18

19 ORCIDs: [0000-0002-2643-3184](https://orcid.org/0000-0002-2643-3184) (S. Karakonstantis); [0000-0002-9526-3852](https://orcid.org/0000-0002-9526-3852) (Ei. Kritsotakis)

20

21 * Correspondence:

22 Evangelos I. Kritsotakis, School of Medicine, University of Crete, 71003 Heraklion, Crete, Greece. Tel.:
23 +30 2810 374619; E-mail: e.kritsotakis@uoc.gr; e.kritsotakis@sheffield.ac.uk

24

25 Abstract word count: 296; Main manuscript word count: 3800.

26 **Abstract**

27 **Background:** Cefiderocol is a last resort option for carbapenem-resistant (CR) Gram-negative
28 bacteria, especially metallo- β -lactamase (MBL)-producing *Pseudomonas aeruginosa* and CR
29 *Acinetobacter baumannii*. Monitoring global levels of cefiderocol non-susceptibility (CFDC-NS) is
30 important.

31 **Objectives:** To systematically collate and examine studies investigating in-vitro CFDC-NS and
32 estimate the global prevalence of CFDC-NS against major Gram-negative pathogens.

33 **Data sources:** PubMed and Scopus, up to May 2023.

34 **Study eligibility criteria:** Eligible were studies reporting CFDC-NS in Enterobacterales, *P. aeruginosa*,
35 *A. baumannii*, or *Stenotrophomonas maltophilia* clinical isolates.

36 **Methods:** Two independent reviewers extracted study data and assessed risk of bias on the
37 population, setting and measurement (susceptibility testing) domains. Binomial-Normal mixed-
38 effects models were applied to estimate CFDC-NS prevalence by species, co-resistance phenotype
39 and breakpoint definition (EUCAST, CLSI, FDA). Sources of heterogeneity were investigated by
40 subgroup and meta-regression analyses.

41 **Results:** In all, 78 studies reporting 82,035 clinical isolates were analysed (87% published between
42 2020 and 2023). CFDC-NS prevalence (EUCAST breakpoints) was low overall, but varied by species [*S.*
43 *maltophilia* 0.4% (95%CI 0.2-0.7%), Enterobacterales 3.0% (95%CI 1.5-6.0%), *P. aeruginosa* 1.4%
44 (95%CI 0.5-4.0%)] and was highest for *A. baumannii* (8.8%, 95%CI 4.9-15.2%). CFDC-NS was much
45 higher in CR Enterobacterales (12.4%, 95%CI 7.3-20.0%) and CR *A. baumannii* (13.2%, 95%CI 7.8-
46 21.5%), but relatively low for CR *P. aeruginosa* (3.5%, 95%CI 1.6-7.8%). CFDC-NS was exceedingly
47 high in NDM-producing Enterobacterales (38.8%, 95%CI 22.6-58.0%), NDM-producing *A. baumannii*
48 (44.7%, 95%CI 34.5-55.4%), and ceftazidime/avibactam-resistant Enterobacterales (36.6%, 95%CI
49 22.7-53.1%). CFDC-NS varied considerably with breakpoint definition, predominantly among CR

50 bacteria. Additional sources of heterogeneity were single-centre investigations and geographical
51 regions.

52 **Conclusions:** CFDC-NS prevalence is low overall, but alarmingly high for specific CR phenotypes
53 circulating in some institutions or regions. Continuous surveillance and updating of global CFDC-NS
54 estimates are imperative while cefiderocol is increasingly introduced into clinical practice. The need
55 to harmonize EUCAST and CLSI breakpoints was evident.

56

57 **Key words:**

58 Cefiderocol; drug resistance; carbapenem-resistant; gram-negative bacteria; prevalence; global
59 epidemiology.

60

61 Introduction

62

63 Pandrug-resistant Gram-negative bacteria (GNB) are increasingly being reported worldwide
64 [1] and are associated with significant mortality [2] and limited treatment options [3, 4]. Among the
65 currently available antimicrobials, cefiderocol is a last resort option, especially for carbapenem-
66 resistant (CR) *Acinetobacter baumannii* and metallo- β -lactamase (MBL)-producing *Pseudomonas*
67 *aeruginosa*, since newer β -lactam- β -lactamase inhibitors (including ceftazidime/avibactam \pm
68 aztreonam, ceftolozane/tazobactam, meropenem/vaborbactam and imipenem/relebactam) are
69 inactive against these pathogens [3, 5].

70 However, as with any new drug, resistance to cefiderocol is increasingly being reported and
71 even preceded its clinical use [6, 7]. Notably, cefiderocol heteroresistance is widespread [8] and
72 could potentially result in emergence of resistance in-vivo during treatment [6] and eventually
73 spread of cefiderocol-resistant strains within and across institutions and geographical regions.
74 Furthermore, various β -lactamases have been reported to significantly reduce cefiderocol
75 susceptibility [6]. Among MBLs, New Delhi metallo- β -lactamase (NDM) appears to be the most likely
76 contributing source to cefiderocol resistance [6, 7]. Ceftazidime/avibactam-resistant isolates are also
77 more likely to be cefiderocol-resistant, either due to being MBL-producing or due to *Klebsiella*
78 *pneumoniae* carbapenemase (KPC) variants conferring cross resistance to cefiderocol [6].

79 This systematic review and meta-analysis aimed to estimate the global prevalence of
80 cefiderocol non-susceptibility (CFDC-NS) in Enterobacterales, *P. aeruginosa*, *A. baumannii* and
81 *Stenotrophomonas maltophilia*, including subgroups of problematic co-resistance phenotypes
82 (carbapenem-resistant, MBL-producing, NDM-producing, ceftazidime/avibactam-resistant and
83 ceftolozane/tazobactam-resistant). In addition, concurrent analyses of different susceptibility
84 breakpoint thresholds (proposed by CLSI [9], FDA [10], and EUCAST [11]) were performed, and
85 variation of CFDC-NS prevalence with study-level characteristics was examined.

86 **Methods**

87

88 **Protocol**

89 This review was registered with the International Prospective Register of Systematic Reviews
90 (registration no. CRD42021265927) and complies with the Preferred Reporting Items for Systematic
91 Reviews and Meta-Analyses guidelines [12].

92

93 **Search strategy, information sources and eligibility criteria**

94 PubMed and Scopus were queried from inception to May 27, 2023, with the search term
95 “cefiderocol OR s-649266”, without language restriction. After de-duplication, retrieved articles
96 were screened for eligibility by one author using the Rayyan online app for collaborative systematic
97 reviews [13]. A second author validated eligibility of included articles.

98 Eligible for review were studies of any type of primary research design if they reported
99 cefiderocol susceptibility proportions of clinical isolates of Enterobacterales, *P. aeruginosa*, *A.*
100 *baumannii* and/or *S. maltophilia*. Exclusion criteria were (in order they were applied): (1) non-
101 primary research articles (e.g. commentaries, editorials, review articles); (2) in vivo infection models
102 in animals; (3) case reports of a single isolate or consecutive isolates from a single patient, (4) studies
103 of selected non-consecutive and/or non-random isolates that could result in selection bias when
104 estimating cefiderocol susceptibility (e.g. isolates selected based on cefiderocol resistance, or studies
105 of patients selected based on receiving treatment with cefiderocol, or series of non-consecutive non-
106 random isolates selected based on specific resistance phenotypes), including experimental studies
107 and randomized controlled trials; (5) irrelevant primary research articles without data of interest to
108 this review (e.g. pharmacokinetic/pharmacodynamic, toxicology studies, non-clinical isolates); and
109 (6) conference abstracts.

110

111 **Data collection process**

112 Full text papers for all eligible studies were obtained and two reviewers extracted data
113 independently using a purpose-built spreadsheet that had been piloted on two eligible studies by all
114 authors. Data extraction from articles written in languages other than English was done with the aid
115 of Google Translate. The following information was extracted from each paper, when provided:
116 geographical location (country or countries) where the study was conducted, number of
117 participating institutions, breakpoint cut-off used to define resistance, methods of susceptibility
118 testing, numbers and proportions of CFDC-NS isolates for each pathogen species, minimum inhibitor
119 concentration (MIC) range, MIC50 and MIC90. Bacterial subgroups of interest were carbapenem
120 (CAR)-resistant Enterobacterales, MBL-producing Enterobacterales, NDM-producing
121 Enterobacterales, ceftazidime/avibactam (CZA)- and ceftolozane/tazobactam (CTA)- resistant
122 Enterobacterales, CR *P. aeruginosa*, MBL-producing *P. aeruginosa*, NDM-producing *P. aeruginosa*,
123 CZA- and CTA-resistant *P. aeruginosa*, CR *A. baumannii*, MBL-producing *A. baumannii* and NDM-
124 producing *A. baumannii*.

125 Overlapping studies reporting duplicate isolates were detected by contrasting information
126 on institutions, authors and periods when the studies were conducted. Some studies contributed
127 more than one set of clinical isolates in different periods, at different institutions/regions, and/or for
128 different co-resistance phenotypes. Such subsets were analysed as separate studies in the meta-
129 analyses.

130

131 **Methods of susceptibility testing**

132 Broth microdilution (BMD) in iron-depleted cation-adjusted Mueller-Hinton broth (ID-
133 CAMHB) (prepared according to recommendations by CLSI [9] or EUCAST [14]) is the currently
134 preferred method for evaluating susceptibility to cefiderocol [9, 11, 15, 16]. ID-CAMHB preparation
135 using human apotransferrin is not recommended due to MIC reproducibility issues [14]. Disk
136 diffusion in standard MH agar (iron-depletion not necessary because iron is bound by the medium) is

137 an alternative, but not recommended for *A. baumannii* [16] and resistance detected by disk
138 diffusion should ideally be confirmed by broth microdilution [17]. Colonies within zone should be
139 taken into account when measuring the zone diameter [15]. In case of studies reporting more than
140 one method, data extraction was based on the following (in order of preference): broth
141 microdilution, disk diffusion, gradient strip. Susceptibility breakpoints for cefiderocol vary.
142 Contemporary breakpoints proposed by FDA [10], CLSI [9] and EUCAST [11] are summarized in the
143 [Supplement \(Section 1\)](#). With respect to EUCAST, non-species related PK/PD-based breakpoints were
144 applied for *A. baumannii* and *S. maltophilia*. In studies reporting a single criterion, susceptibility
145 percentages for other breakpoint criteria were inferred based on reported MIC ranges or MIC
146 distribution data when available (when maximum MIC was below the susceptibility breakpoint a 0%
147 non-susceptibility was inferred).

148

149 **Definitions of co-resistance phenotypes**

150 Underlying co-resistance phenotypes were categorized as any phenotype, CR, MBL-
151 producing, NDM-producing, CZA-resistant, or CTA-resistant. “Any phenotype” referred to studies
152 with non-selected isolates of mixed resistance phenotypes. Studies selecting isolates solely based on
153 being CR or CZA-resistant or CTA-resistant or MBL-producing, were reported separately from the
154 “any phenotype” category to avoid overestimating CFDC-NS prevalence, which was expected to be
155 higher for those phenotypes [6]. Similarly, studies selecting isolates solely based on being CZA-
156 resistant, CTA-resistant or MBL-producing isolates were reported separately from the CR category,
157 whereas studies selecting solely NDM-producing isolates were reported separately from the MBL
158 category. Depending on data availability and definitions in the studies, CR was defined, in order of
159 preference, as meropenem MIC>8mg/L, or meropenem resistance or non-susceptibility according to
160 another study-defined breakpoint, or non-susceptibility as defined in the study (not necessarily
161 based on meropenem), or carbapenemase-production.

162

163 **Risk of bias assessment**

164 Two reviewers examined independently each study for risk of bias concerning two main
165 domains applicable to this review [18]: (a) population and setting and (b) condition measurement
166 (validity and standardization of the susceptibility testing method). Discrepancies in risk of bias
167 assessments were resolved by discussion and consensus. Items for each domain were adapted from
168 the Joanna-Briggs critical appraisal tool for prevalence studies [18, 19]. Items and their
169 interpretation as used in this review are described in the [Supplement \(Section 2\)](#). Studies at
170 moderate or high risk of bias in either domain were categorized as moderate-to-high risk overall,
171 while studies at low risk of bias in both domains were categorized as low risk of bias overall.

172

173 **Meta-analysis methods**

174 The primary outcome for meta-analysis was CFDC-NS prevalence, stratified by combinations
175 of microorganism species, definition of breakpoints and underlying co-resistance phenotype.
176 Population-averaged proportions were estimated using a random intercept logistic regression model
177 with maximum likelihood estimation [20]. The model assumed a Binomial distribution for the
178 observed number of CFDC-NS isolates in each study and a Normal distribution for the random
179 population-level effects following the logit transformation. This approach correctly handles
180 proportions near 0% or 100% (when variance tends towards zero and classic inverse variance
181 weights are problematic), [21] and maintains the confidence limits of pooled proportions within the
182 zero to one range. The resulting confidence interval (CI) contains highly probable values for the
183 population-averaged (pooled) prevalence proportion of CFDC-NS.

184 Higgin-Thompson's I^2 statistic was used as a summary index of the amount of variability of
185 CFDC-NS proportions across studies that cannot be attributed to sampling error. Because I^2 is usually
186 high and may not be discriminative for prevalence data [22], we additionally reported between-
187 study variance (τ^2) with respective 95% prediction interval (PI). The PI describes the range CFDC-NS
188 proportions that can be expected in new studies or settings [23]. We used summary forest plots to

189 present pooled estimates with heterogeneity statistics for each microorganism and each different
190 combination of breakpoint threshold with co-resistance phenotype. Additionally, we constructed
191 forest plots for the study-specific data used in each meta-analysis to illustrate the distributions of
192 CFDC-NS proportions across the studies along with 95% CIs calculated by Wilson's score method
193 (presented in the [Supplement](#)).

194 To examine potential sources of variation in CFDC-NS prevalence, we conducted a series of
195 univariate meta-regressions with the Binomial-Normal mixed-effects model. We applied this to
196 carbapenem-resistant *Enterobacteriales*, *P. aeruginosa*, *A. baumannii* and *K. pneumoniae* based on
197 the CLSI breakpoints, as this was the most frequent combination of breakpoints with co-resistance
198 phenotype with a minimum of 15 studies available for each meta-regression. Odds ratios (ORs) with
199 respective 95% CI were calculated to summarise the strength and direction of associations between
200 study-level covariates and CFDC-NS prevalence. A covariate-specific R^2 was calculated as the portion
201 of between-study variance that was reduced after the inclusion of that covariate in a null model.
202 Moreover, for each covariate level we calculated pooled estimates of CFDC-NS prevalence based on
203 subgroup analysis. Candidate covariates were decided a priori in our study protocol. The following
204 study-level variables were examined: year when data collection ended, geographical region (WHO
205 classification), multinational setting (yes/no), multicentre setting (yes/no), and risk of bias (classified
206 as either low or moderate-to-high). Despite our protocol plans, we were unable to examine
207 substantive characteristics related to clinical setting (such as type and level of care, age of the
208 patients, clinical specialty, and type of infection), which were largely unreported in the studies. The
209 number of retrieved studies was inadequate to justify multivariable meta-regression.
210 All analyses were carried out in STATA (Version 17; Statcorp, College Station, TX, USA).

211

212 **Results**

213

214 **Study characteristics**

215 The flow chart of the review is depicted in [Figure 1](#). A total of 78 studies were eligible for
216 review [8, 16, 21, 24-98], which contributed 86 independent sets of data for analysis and reported
217 82,035 clinical isolates in total. Main characteristics of the studies are summarized in the
218 [Supplement, Sections 3-6](#). Several studies were identified as having overlapping collections of
219 isolates as a result of the SIDERO-WT surveillance study being conducted yearly (2014-2019) in
220 several countries in North America and Europe [25, 26, 55, 56, 58, 99-105]. Only non-overlapping
221 data were collected for meta-analysis (see [Supplement, Section 7](#)). Most studies (87%) were
222 published in the last four years (2020-2023). Regions most represented were Europe (50% of data
223 sets), the Americas (33%), and the Western Pacific Region (17%) ([Supplement, Section 5](#)). Data for
224 Enterobacterales were reported in 53 studies [8, 16, 26-31, 33, 34, 36-38, 41-48, 51, 54, 56, 57, 59,
225 60, 62, 64-69, 72, 75-85, 87, 91, 92, 95, 96], *P. aeruginosa* in 41 studies [7, 8, 16, 26, 28, 33, 34, 36,
226 39, 41-43, 45-49, 52-54, 56, 57, 61, 63, 66, 70, 71, 73-75, 78, 79, 83, 85, 86, 88, 89, 91, 94, 97, 106],
227 *A. baumannii* in 35 studies [8, 16, 24, 26, 28, 30, 33-36, 39, 41-43, 45-48, 50, 52-54, 56, 57, 61, 66,
228 75, 78, 79, 85, 86, 90, 91, 93, 107] and *S. maltophilia* in 19 studies [8, 16, 26, 28, 30, 33, 40-42, 48,
229 52-54, 61, 74, 75, 78, 79, 85].

230

231 **Risk of bias assessment**

232 Overall risk of bias was moderate-to-high in most (94%) study sets of data, predominantly
233 concerning moderate or high risks in the population and setting domains (86% of data sets). The
234 latter was mostly due to inadequate descriptions of the characteristics of the study populations and
235 insufficient sample sizes in individual studies of the pathogen populations of interest ([Supplement,](#)
236 [Section 6](#)). About half (n=46; 54%) of the study sets were classified as moderate-to-high risk of bias
237 in the domain of condition measurement. In about half of the cases (n=44, 51%), the studies lacked a
238 clear definition or citation of the method for interpreting trailing (broth microdilution) or colonies
239 within zone (disk diffusion). There were 14 data sets for which a method other than broth

240 microdilution was used (n=9 disk diffusion [8, 36, 37, 51, 65, 72, 75, 88, 92, 95], n=5 gradient strip
241 [36, 68, 69, 94, 97]). Apotransferrin for medium preparation was reported on 4 data sets (2 studies
242 [60, 61]).

243

244 **Cefiderocol activity against Enterobacterales**

245 [Figure 2](#) is a summary forest plot of CFDC-NS prevalence estimates in Enterobacterales for
246 different combinations of breakpoints definition and co-resistance phenotype. The respective forest
247 plots for each separate meta-analysis and a summary table are available in [the Supplement \(Section](#)
248 [8\)](#). Data on CFDC-NS against the various Enterobacterales species (*Klebsiella* spp, *E. coli*,
249 *Enterobacter* spp, *Serratia* spp, *Citrobacter* spp, *Proteus* spp, *Morganella morganii*) are also available
250 in the [Supplement \(Section 9\)](#).

251 Using the EUCAST breakpoint thresholds, the pooled CFDC-NS prevalence was generally low
252 (3.0%, 95% CI 1.5-6.0%), but much higher in CR Enterobacterales (12.4%, 95% CI 7.3-20.0%), and
253 exceedingly high in MBL-producing (24.9%, 95% CI 16.6-35.5%), NDM-producing (38.8%, 95% CI
254 22.6-58.0%) and CZA-resistant (36.6%, 95% CI 22.7-53.1%) Enterobacterales. Notable differences in
255 CFDC-NS percentages were evident when contrasting the results between the EUCAST breakpoints
256 and the CLSI breakpoints in [Figure 2](#). Pooled CFDC-NS percentages based on the former were much
257 greater than the latter, especially among CR (12.4% vs 3.8%), MBL-producing (24.9% vs 13.0%),
258 NDM-producing (38.7% vs 18.7%) and CZA-resistant (36.6% vs 8.3%) Enterobacterales.

259

260 **Cefiderocol activity against *P. aeruginosa***

261 As seen in [Figure 3](#), CFDC-NS prevalence (EUCAST breakpoints) was generally low (1.4%, 95%
262 CI 0.5-4.0%), even among CR (3.5%, 95% CI 1.6-7.8%), and MBL-producing (1.8%, 95% CI 0.3-10.4%),
263 CZA-resistant (6.8%, 95% CI 3.1-14.6%) and CTA-resistant (8.3%, 95% CI 4.1-16.0%) isolates. CFDR-NS
264 proportion was highest among NDM-producing isolates (22.9%, 95% CI 8.1-49.7%) but this estimate
265 was based on few isolates (n=51). Notable differences in CFDC-NS prevalence estimates were

266 observed comparing CLSI to EUCAST and FDA definitions of breakpoints among the CR *P. aeruginosa*
267 isolates (0.8% vs 3.5% vs 14.6%), especially for the MBL-producers (1.6% vs 1.8% vs 23.3%), NDM-
268 producers (19.5% vs 22.9% vs 58.7%), CZA-resistant (1.7% vs 6.8% vs 19.5%) and CTA-resistant (2.2%
269 vs 8.3% vs 15.1%) isolates. The respective forest plots for each meta-analysis of each combination of
270 breakpoint criterion and co-resistance phenotype, together with a summary table, are available in
271 the [Supplement \(Section 10\)](#).

272

273 **Cefiderocol activity against *A. baumannii***

274 The summary forest plot of subgroup-averaged proportions of CFDC-NS against *A. baumannii*,
275 by co-resistance phenotype and breakpoints definition, is depicted in [Figure 4](#). Respective forest
276 plots for each meta-analysis and summary table are available in the [Supplement \(Section 11\)](#). Overall
277 CFDC-NS prevalence in *A. baumannii* was higher compared to other species. CFDC-NS proportions
278 (EUCAST breakpoints) were similar in the “any phenotype” (8.8%, 95% CI 4.9-15.2%,) and the CR
279 (13.2%, 95% CI 7.8-21.5%) groups of *A. baumannii*, reflecting the high burden of carbapenem-
280 resistance in this organism (i.e. sets of non-selected isolates classified as any/mixed phenotype
281 included large portions of CR isolates). CFDC-NS prevalence was much higher among MBL-producing
282 (40.9%, 95% CI 31.4-51.1%) and NDM-producing (44.7%, 95% CI 34.5-55.4%) *A. baumannii* isolates,
283 with the majority of MBL-producing isolates being NDM-producers. Similar to other species, CFDC-
284 NS prevalence was much lower when CLSI breakpoints were used as opposed to the EUCAST and
285 FDA cut-offs among CR *A. baumannii* isolates (8.5% vs 13.2% vs 26.6%, respectively), especially for
286 the MBL-producers (20.4% vs 40.9% vs 53.1%) and the NDM-producers (23.0% vs 44.7% vs 71.3%,
287 respectively).

288

289 **Cefiderocol activity against *S. maltophilia***

290 Cefiderocol non-susceptibility against *S. maltophilia* was very low, irrespective of the
291 breakpoint definition used. CFDC-NS prevalence was 0.2% (95% CI 0.1-0.4%) where earlier CLSI

292 breakpoint criteria were used, 0.1% (95% CI 0.0-3.7%) when the new CLSI criteria were used, and
293 0.4% (95% CI 0.2-0.7%) with EUCAST breakpoints. In the largest study contributing the majority of
294 data for *S. maltophilia*, the prevalence of CFDC-NS was 2.4% based on the new CLSI breakpoints,
295 compared to 0.4% based on EUCAST and 0.2% based on prior CLSI breakpoints. A summary forest
296 plot and respective forest plots for each meta-analysis are available in the [Supplement \(Section 12\)](#).

297

298 **Heterogeneity**

299 As evident from the heterogeneity statistics and prediction intervals in [Figures 2-4](#), the data
300 were characterised by considerable variability, even within the subgroups defined by combinations
301 of co-resistance phenotype and breakpoint definition. Potential sources of variation in CFDC-NS
302 prevalence were examined among CR isolates (CLSI breakpoints) by a series of univariate meta-
303 regressions and the results are presented in the [Supplement \(Section 13\)](#). Indicatively, we present
304 the results of the investigation for Enterobacterales in [Table 1](#). These investigations revealed that
305 single-centre study designs were associated with higher CFDC-NS prevalence, explaining a large
306 portion of the variance among Enterobacterales (R^2 28%) and *A. baumannii* (R^2 21%). Regional
307 variation was also observed. The results also suggested, albeit with a high degree of uncertainty,
308 that CFDC-NS prevalence was higher in the Americas than elsewhere for CR *K. pneumoniae* (OR 1.9;
309 95% CI 0.2 - 17.4), higher in the Western Pacific Region than elsewhere for CR Enterobacterales (OR
310 3.3; 95% CI 0.4 – 27.0) and higher in Europe than elsewhere for CR *P. aeruginosa* (OR 1.6; 95% CI 0.3
311 – 9.6). Consistently in all meta-regressions, there was no evidence of variation in CFDC-NS
312 prevalence according to risk of bias assessments.

313

314 **Discussion**

315

316 This systematic review and meta-analysis revealed differential pathogen-specific variation in the
317 global prevalence of CFDC-NS, which was seen to be low for Enterobacterales, *P. aeruginosa*, and *S.*
318 *maltophilia* but much higher against *A. baumannii*. Significant variability was also observed within
319 each species, depending on the underlying antimicrobial co-resistance phenotype. Overall,
320 cefiderocol appeared to retain relatively good activity against CR bacteria (especially CR *S.*
321 *maltophilia* and *P. aeruginosa*), but for certain phenotypes (MBL/NDM-producing Enterobacterales
322 and *A. baumannii*, and CZA-resistant Enterobacterales) CFDC-NS is exceedingly high.

323 Substantial heterogeneity of CFDC-NS prevalence among the studies was highlighted in this
324 review and was found to persist even within presumably homogeneous subgroups of isolates
325 defined by different combinations of co-resistance phenotype and CFDC breakpoint threshold. There
326 was some evidence of regional variation, which might reflect differences in the epidemiology of
327 carbapenemases between the regions, with selected carbapenemases having conferred cross-
328 resistance to CFDC [6]. In addition, antimicrobial resistance might vary significantly among different
329 clinical settings, but despite our initial plans, relevant data were largely unreported in the studies.
330 Therefore, the population-averaged susceptibility estimates reported in this study are probably not
331 generalizable to individual institutions and/or specific clinical settings (as indicated by wide
332 prediction intervals), but serve to illustrate that despite high susceptibility to cefiderocol overall,
333 there are settings where high non-susceptibility has been reported. Notably, the meta-regression
334 models consistently attributed higher odds of CFDC-NS to single-centre studies. This might reflect
335 clonal spreads or outbreaks of CR clones, possibly associated with β -lactamases, that have resulted
336 in decreased cefiderocol susceptibility locally in some institutions or regions. Nevertheless, the lower
337 prediction limits of CFDC-NS prevalence were considerably higher than zero for several co-resistance
338 phenotypes examined in this review; thereby a high index of suspicion should be maintained when
339 empirically administering cefiderocol, particularly in settings of aggravated antimicrobial resistance,
340 or when *A. baumannii* is implicated.

341 Cefiderocol, exhibiting greater stability against β -lactamases (ESBL, AmpC, and all classes of
342 carbapenemases including MBLs) can inhibit (especially based on CLSI breakpoints) the vast majority
343 of Gram-negative isolates that are not-susceptible to carbapenems, ceftazidime/avibactam,
344 ceftolozane/tazobactam and colistin [54, 58, 108, 109]. However, despite very high susceptibility
345 rates in initial reports worldwide, non-susceptibility to cefiderocol appears to be more common in
346 CR Gram-negative pathogens when applying the more stringent breakpoints proposed by EUCAST or
347 FDA (the latter for non-fermenting Gram-negative bacteria) [16, 47]. In line with the current meta-
348 analysis, a prior systematic review on mechanisms of CFDC-NS by the same authors, identified
349 several β -lactamases (and various other mechanisms) that may result in higher MIC of cefiderocol,
350 notably NDM and KPC variants conferring resistance for CZA [6]. Of interest, combination of
351 cefiderocol with β -lactamases may be able to overcome resistance [6, 110].

352 Significant differences in the levels of CFDC-NS prevalence were noted when different proposed
353 thresholds for antimicrobial breakpoints were used, which were pronounced among the CR
354 phenotypes, especially MBL/NDM-producing isolates, similar to a previous report [111]. This has
355 important clinical implications as the greatest clinical utility of cefiderocol is against infections by CR
356 Gram-negative bacteria, particularly the MBL-producing isolates, which are associated with limited
357 treatment options [3]. Therefore, harmonization of breakpoints is urgently needed, as well
358 development of accurate in vitro susceptibility testing considering limitations of current methods
359 [17].

360 Between-study variability is a main source of uncertainty for any meta-analysis and we
361 attempted to account for heterogeneity by using a random effects model when pooling prevalence
362 data and identify main sources of heterogeneity by subgroup and meta-regression analyses.
363 Nevertheless, there are other important limitations to our investigation that should be mentioned.
364 First, comparisons between CFDC-NS prevalence rates for different breakpoint criteria proposed by
365 CLSI, FDA, and EUCAST were partly indirect because not all studies reported susceptibility data using
366 all breakpoint definitions. Second, for a number of studies we inferred the susceptibility percentages

367 based on the maximum MICs being below the breakpoints. For example, in studies reporting
368 susceptibilities based on CLSI breakpoints (MIC \leq 4 mg /L) without reporting detailed MIC distribution
369 data, the susceptibility proportions based on EUCAST breakpoints or FDA breakpoints were
370 estimable only when the maximum MIC was lower than or equal to the EUCAST or FDA breakpoint
371 respectively (i.e. 100% susceptible). Bias from this approach would most likely be towards
372 underestimating CFDC-NS prevalence. Third, data on cefiderocol susceptibility for specific CR
373 phenotypes (MBL, NDM) were limited, and reporting bias is possible. Finally, cefiderocol
374 susceptibility testing has limitations including poor reproducibility of broth microdilution and disk
375 diffusion for *A. baumannii*, difficulties in interpretation due to trailing in broth microdilution and
376 colonies within zones of inhibition in disk diffusion, and inoculum-dependent MIC [17]. In our
377 review, most (84%) studies used broth microdilution, but about half were considered at moderate or
378 high risk of bias for not clearly reporting interpretation of trailing in broth microdilution.
379 Nevertheless, such lack of reporting does not necessarily mean that interpretation of trailing was
380 inappropriate. Moreover, meta-regression analyses did not detect variation in CFDC-NS prevalence
381 according to risk of bias assessments in the condition measurement domain.

382 In conclusion, cefiderocol currently maintains a good level of activity against major Gram-
383 negative pathogens and CFDC-NS prevalence is low overall. However, CFDC-NS prevalence
384 proportions were alarmingly high in specific CR phenotypes circulating in some institutions or
385 regions. A high index of suspicion for CFDC-NS is required concerning MBL- (predominantly NDM-)
386 producing Enterobacterales and *A. baumannii*, NDM-producing *P. aeruginosa*, as well as CZA-
387 resistant Enterobacterales, due to the possibility of emergence and spread of isolates with β -
388 lactamases that may significantly increase cefiderocol's MIC. Antimicrobial stewardship, infection
389 control and continued surveillance at the local level, as well as regular updating and reporting of
390 global CFDC-NS estimates, are imperative for preventing or delaying emerging resistance against
391 cefiderocol. Harmonization of EUCAST and CLSI breakpoints would help such efforts.

392

393 **Transparency declaration**

394

395 **Conflict of interest.** The authors declare that they have no known competing financial interests or
396 personal relationships that could have appeared to influence the work reported in this paper.

397

398 **Funding.** No external funding was received for this study, which was carried out as part of our
399 routine work.

400

401 **Author contributions.** Conception: S.K. study design: S.K. and E.I.K.; literature searches, screening
402 and data extraction: M.R. , L.V. and S.K.; statistical analysis and graphics: E.I.K.; writing of the article:
403 S.K. and E.I.K.; data interpretation, critical revisions and approval of the manuscript by all authors.

404

References

- 406 [1] S. Karakonstantis, E.I. Kritsotakis, A. Gikas, Pandrug-resistant Gram-negative bacteria: a
407 systematic review of current epidemiology, prognosis and treatment options, *J Antimicrob*
408 *Chemother* 75(2) (2019) 271–282.
- 409 [2] S. Karakonstantis, A. Gikas, E. Astrinaki, E.I. Kritsotakis, Excess mortality due to pandrug-resistant
410 *Acinetobacter baumannii* infections in hospitalized patients, *Journal of Hospital Infection* 106(3)
411 (2020) 447-453.
- 412 [3] S. Karakonstantis, E. Kritsotakis, A. Gikas, Treatment Options for *K. pneumoniae*, *P. aeruginosa*
413 and *A. baumannii* Co-resistant to Carbapenems, Aminoglycosides, Polymyxins and Tigecycline. An
414 Approach Based on the Mechanisms of Resistance to Carbapenems., *Infection* 48(6) (2020) 835-851.
- 415 [4] S. Karakonstantis, P. Ioannou, G. Samonis, D.P. Kofteridis, Systematic review of antimicrobial
416 combination options for pandrug-resistant *Acinetobacter baumannii*, *Antibiotics (Basel, Switzerland)*
417 (2021).
- 418 [5] Y. Doi, Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections, *Clinical*
419 *Infectious Diseases* 69(Supplement_7) (2019) S565-S575.
- 420 [6] S. Karakonstantis, M. Rousaki, E.I. Kritsotakis, Cefiderocol: Systematic Review of Mechanisms of
421 Resistance, Heteroresistance and In Vivo Emergence of Resistance, *Antibiotics* 11(6) (2022) 723.
- 422 [7] C. Wang, D. Yang, Y. Wang, W. Ni, Cefiderocol for the Treatment of Multidrug-Resistant Gram-
423 Negative Bacteria: A Systematic Review of Currently Available Evidence, *Frontiers in pharmacology*
424 13 (2022) 896971.
- 425 [8] J.E. Choby, T. Ozturk, S.W. Satola, J.T. Jacob, D.S. Weiss, Widespread cefiderocol heteroresistance
426 in carbapenem-resistant Gram-negative pathogens, *The Lancet Infectious Diseases* 21(5) (2021) 597-
427 598.
- 428 [9] CLSI, Performance Standards for Antimicrobial Susceptibility Testing. 32nd ed. CLSI supplement
429 M100., Clinical Laboratory Standards Institute, Wayne, 2022.
- 430 [10] FDA, Cefiderocol Injection. FDA Identified Breakpoints.
431 <<https://www.fda.gov/drugs/development-resources/cefiderocol-injection>>, 2020 (accessed
432 22/12/2022.2022).
- 433 [11] The European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for
434 interpretation of MICs and zone diameters. Version 12.0. <<http://www.eucast.org/>>, 2023 (accessed
435 2023-03-24.2023).
- 436 [12] M.J. Page, D. Moher, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M.
437 Tetzlaff, E.A. Akl, S.E. Brennan, R. Chou, J. Glanville, J.M. Grimshaw, A. Hróbjartsson, M.M. Lalu, T. Li,
438 E.W. Loder, E. Mayo-Wilson, S. McDonald, L.A. McGuinness, L.A. Stewart, J. Thomas, A.C. Tricco, V.A.
439 Welch, P. Whiting, J.E. McKenzie, PRISMA 2020 explanation and elaboration: updated guidance and
440 exemplars for reporting systematic reviews, *BMJ* 372 (2021) n160.
- 441 [13] M. Ouzzani, H. Hammady, Z. Fedorowicz, A. Elmagarmid, Rayyan—a web and mobile app for
442 systematic reviews, *Systematic Reviews* 5(1) (2016) 210.
- 443 [14] M.A. Hackel, M. Tsuji, Y. Yamano, R. Echols, J.A. Karlowsky, D.F. Sahm, Reproducibility of broth
444 microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-
445 depleted cation-adjusted Mueller-Hinton broth, *Diagnostic microbiology and infectious disease* 94(4)
446 (2019) 321-325.
- 447 [15] P.J. Simner, R. Patel, Cefiderocol Antimicrobial Susceptibility Testing Considerations: the
448 Achilles' Heel of the Trojan Horse?, *Journal of clinical microbiology* 59(1) (2020).
- 449 [16] C.P. Morris, Y. Bergman, T. Tekle, J.A. Fissel, P.D. Tamma, P.J. Simner, Cefiderocol Antimicrobial
450 Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison of Disk
451 Diffusion to Broth Microdilution, *Journal of clinical microbiology* 59(1) (2020).

452 [17] P.J. Simner, E.L. Palavecino, M.J. Satlin, A.J. Mathers, M.P. Weinstein, J.S. Lewis, 2nd, R.
453 Humphries, Potential of Inaccurate Cefiderocol Susceptibility Results: a CLSI AST Subcommittee
454 Advisory, *Journal of clinical microbiology* 61(4) (2023) e0160022.

455 [18] C.B. Migliavaca, C. Stein, V. Colpani, Z. Munn, M. Falavigna, Quality assessment of prevalence
456 studies: a systematic review, *Journal of clinical epidemiology* 127 (2020) 59-68.

457 [19] Z. Munn, S. Moola, K. Lisy, D. Riitano, C. Tufanaru, Methodological guidance for systematic
458 reviews of observational epidemiological studies reporting prevalence and cumulative incidence
459 data, *International journal of evidence-based healthcare* 13(3) (2015) 147-53.

460 [20] L. Lin, H. Chu, Meta-analysis of Proportions Using Generalized Linear Mixed Models,
461 *Epidemiology* 31(5) (2020) 713-717.

462 [21] J. Xu, H. Guo, L. Li, F. He, Molecular epidemiology and genomic insights into the transmission of
463 carbapenem-resistant NDM-producing *Escherichia coli*, *Computational and structural biotechnology*
464 *journal* 21 (2023) 847-855.

465 [22] C.B. Migliavaca, C. Stein, V. Colpani, T.H. Barker, P.K. Ziegelmann, Z. Munn, M. Falavigna, Meta-
466 analysis of prevalence: I(2) statistic and how to deal with heterogeneity, *Res Synth Methods* 13(3)
467 (2022) 363-367.

468 [23] J. IntHout, J.P.A. Ioannidis, M.M. Rovers, J.J. Goeman, Plea for routinely presenting prediction
469 intervals in meta-analysis, *BMJ open* 6(7) (2016) e010247.

470 [24] C. Ballesté-Delpierre, Á. Ramírez, L. Muñoz, C. Longshaw, I. Roca, J. Vila, Assessment of In Vitro
471 Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of
472 *Acinetobacter baumannii* Clinical Isolates, *Antibiotics (Basel, Switzerland)* 11(2) (2022).

473 [25] F.J. Candel, A. Santerre Henriksen, C. Longshaw, Y. Yamano, A. Oliver, In vitro activity of the
474 novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of
475 infection, *Clinical microbiology and infection : the official publication of the European Society of*
476 *Clinical Microbiology and Infectious Diseases* 28(3) (2022) 447.e1-447.e6.

477 [26] J.A. Karlowsky, M.A. Hackel, M. Takemura, Y. Yamano, R. Echols, D.F. Sahm, In Vitro
478 Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational
479 SIDERO-WT Surveillance Studies, 2014 to 2019, *Antimicrobial agents and chemotherapy* 66(2) (2022)
480 e0199021.

481 [27] P. Lan, Y. Lu, Z. Chen, X. Wu, X. Hua, Y. Jiang, J. Zhou, Y. Yu, Emergence of High-Level Cefiderocol
482 Resistance in Carbapenem-Resistant *Klebsiella pneumoniae* from Bloodstream Infections in Patients
483 with Hematologic Malignancies in China, *Microbiology spectrum* 10(2) (2022) e0008422.

484 [28] D. Shortridge, J.M. Streit, R. Mendes, M. Castanheira, In Vitro Activity of Cefiderocol against U.S.
485 and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial
486 Surveillance Program, *Microbiology spectrum* 10(2) (2022) e0271221.

487 [29] Q. Wang, L. Jin, S. Sun, Y. Yin, R. Wang, F. Chen, X. Wang, Y. Zhang, J. Hou, Y. Zhang, Z. Zhang, L.
488 Luo, Z. Guo, Z. Li, X. Lin, L. Bi, H. Wang, Occurrence of High Levels of Cefiderocol Resistance in
489 Carbapenem-Resistant *Escherichia coli* before Its Approval in China: a Report from China CRE-
490 Network, *Microbiology spectrum* (2022) e0267021.

491 [30] Q. Wang, L. Jin, S. Sun, Y. Yin, R. Wang, F. Chen, X. Wang, Y. Zhang, J. Hou, Y. Zhang, Z. Zhang, L.
492 Luo, Z. Guo, Z. Li, X. Lin, L. Bi, H. Wang, Occurrence of High Levels of Cefiderocol Resistance in
493 Carbapenem-Resistant *Escherichia coli* before Its Approval in China: a Report from China CRE-
494 Network, *Microbiology spectrum* 10(3) (2022) e0267021.

495 [31] Q. Zhang, N. Neidig, T.Y. Chu, C. Divoky, J. Carpenter, C. Lee-Hsiao, H. Threatt, R. Sultana, K.
496 Bush, In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-
497 nonsusceptible Enterobacterales isolates, *Diagnostic microbiology and infectious disease* 103(1)
498 (2022) 115651.

499 [32] J.C. Abdul-Mutakabbir, L. Nguyen, P.T. Maassen, K.C. Stamper, R. Kebriaei, K.S. Kaye, M.
500 Castanheira, M.J. Rybak, In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant
501 *Acinetobacter baumannii*, *Antimicrobial agents and chemotherapy* 65(9) (2021) e0264620.

502 [33] M. Albano, M.J. Karau, A.N. Schuetz, R. Patel, Comparison of Agar Dilution to Broth
503 Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli, *Journal of*
504 *clinical microbiology* 59(1) (2020).

505 [34] S.S. Bhagwat, N.J. Legakis, T. Skalidis, A. Loannidis, C. Goumenopoulos, P.R. Joshi, R. Shrivastava,
506 S.R. Palwe, H. Periasamy, M.V. Patel, S. Chatzipanagiotou, In vitro activity of cefepime/zidebactam
507 (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek
508 hospitals, *Diagnostic microbiology and infectious disease* 100(3) (2021) 115327.

509 [35] D. Carcione, C. Siracusa, A. Sulejmani, R. Migliavacca, A. Mercato, A. Piazza, L. Principe, N.
510 Clementi, N. Mancini, V. Leoni, J. Intra, In Vitro Antimicrobial Activity of the Siderophore
511 Cephalosporin Cefiderocol against *Acinetobacter baumannii* Strains Recovered from Clinical
512 Samples, *Antibiotics (Basel, Switzerland)* 10(11) (2021).

513 [36] B. Ghebremedhin, P. Ahmad-Nejad, In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-
514 Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia,
515 Germany, *Pathogens* 10(10) (2021).

516 [37] A.S. Jacob, G.L. Chong, K. Lagrou, M. Depypere, S. Desmet, No in vitro activity of cefiderocol
517 against OXA-427-producing Enterobacterales, *J Antimicrob Chemother* 76(12) (2021) 3317-3318.

518 [38] Y.L. Lee, W.C. Ko, W.S. Lee, P.L. Lu, Y.H. Chen, S.H. Cheng, M.C. Lu, C.Y. Lin, T.S. Wu, M.Y. Yen,
519 L.S. Wang, C.P. Liu, P.L. Shao, Z.Y. Shi, Y.S. Chen, F.D. Wang, S.H. Tseng, C.N. Lin, Y.H. Chen, W.H.
520 Sheng, C.M. Lee, H.J. Tang, P.R. Hsueh, In-vitro activity of cefiderocol, cefepime/zidebactam,
521 cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against
522 carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter
523 Antimicrobial Resistance in Taiwan (SMART) in 2017-2020, *International journal of antimicrobial*
524 *agents* 58(3) (2021) 106377.

525 [39] P.Y. Liu, W.C. Ko, W.S. Lee, P.L. Lu, Y.H. Chen, S.H. Cheng, M.C. Lu, C.Y. Lin, T.S. Wu, M.Y. Yen,
526 L.S. Wang, C.P. Liu, P.L. Shao, Y.L. Lee, Z.Y. Shi, Y.S. Chen, F.D. Wang, S.H. Tseng, C.N. Lin, Y.H. Chen,
527 W.H. Sheng, C.M. Lee, H.J. Tang, P.R. Hsueh, In vitro activity of cefiderocol,
528 cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other
529 comparative agents against carbapenem-non-susceptible *Pseudomonas aeruginosa* and
530 *Acinetobacter baumannii* isolates associated from bloodstream infection in Taiwan between 2018-
531 2020, *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi* (2021).

532 [40] M. Biagi, A. Vialichka, M. Jurkovic, T. Wu, A. Shajee, M. Lee, S. Patel, R.E. Mendes, E. Wenzler,
533 Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or
534 Trimethoprim-Sulfamethoxazole against Multidrug-Resistant *Stenotrophomonas maltophilia*,
535 *Antimicrob Agents Chemother* 64(9) (2020).

536 [41] M. Delgado-Valverde, M.D.C. Conejo, L. Serrano, F. Fernández-Cuenca, Á. Pascual, Activity of
537 cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, *Acinetobacter*
538 *baumannii*, *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia*, *J Antimicrob Chemother*
539 75(7) (2020) 1840-1849.

540 [42] A.R. Golden, H.J. Adam, M. Baxter, A. Walkty, P. Lagacé-Wiens, J.A. Karlowsky, G.G. Zhanel, In
541 Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli
542 Isolated from Patients in Canadian Intensive Care Units, *Diagnostic microbiology and infectious*
543 *disease* 97(1) (2020) 115012.

544 [43] A. Iregui, Z. Khan, D. Landman, J. Quale, Activity of Cefiderocol Against Enterobacterales,
545 *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* Endemic to Medical Centers in New York
546 City, *Microbial drug resistance (Larchmont, N.Y.)* 26(7) (2020) 722-726.

547 [44] B.D. Johnston, P. Thuras, S.B. Porter, M. Anacker, B. VonBank, P. Snippes Vagnone, M. Witwer,
548 M. Castanheira, J.R. Johnson, Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline
549 against Carbapenem-Resistant *Escherichia coli* Isolates from the United States and International Sites
550 in Relation to Clonal Background, Resistance Genes, Coresistance, and Region, *Antimicrobial agents*
551 *and chemotherapy* 64(10) (2020).

552 [45] M. Kresken, M. Korte-Berwanger, S.G. Gatermann, Y. Pfeifer, N. Pfennigwerth, H. Seifert, G.
553 Werner, In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from
554 Germany, *International journal of antimicrobial agents* 56(4) (2020) 106128.

555 [46] C. Longshaw, D. Manissero, M. Tsuji, R. Echols, Y. Yamano, In vitro activity of the siderophore
556 cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-
557 negative bacteria from Europe, *JAC-antimicrobial resistance* 2(3) (2020).

558 [47] S. Mushtaq, Z. Sadouki, A. Vickers, D.M. Livermore, N. Woodford, In Vitro Activity of Cefiderocol,
559 a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria, *Antimicrobial
560 agents and chemotherapy* 64(12) (2020).

561 [48] K.V.I. Rolston, B. Gerges, S. Shelburne, S.L. Aitken, I. Raad, R.A. Prince, Activity of Cefiderocol
562 and Comparators against Isolates from Cancer Patients, *Antimicrobial agents and chemotherapy*
563 64(5) (2020).

564 [49] D.A. Talan, S.S. Takhar, A. Krishnadasan, W.R. Mower, D.J. Pallin, M. Garg, J. Femling, R.E.
565 Rothman, J.C. Moore, A.E. Jones, F. Lovecchio, J. Jui, M.T. Steele, A.M. Stubbs, W.K. Chiang, G.J.
566 Moran, Emergence of Extended-Spectrum β -Lactamase Urinary Tract Infections Among Hospitalized
567 Emergency Department Patients in the United States, *Ann Emerg Med* 77(1) (2021) 32-43.

568 [50] V. Trebosc, B. Schellhorn, J. Schill, V. Lucchini, J. Bühler, M. Bourotte, J.J. Butcher, M. Gitzinger,
569 S. Lociuro, C. Kemmer, G.E. Dale, In vitro activity of rifabutin against 293 contemporary carbapenem-
570 resistant *Acinetobacter baumannii* clinical isolates and characterization of rifabutin mode of action
571 and resistance mechanisms, *J Antimicrob Chemother* (2020).

572 [51] O. Xie, K. Cisera, L. Taylor, C. Hughes, B. Rogers, Clinical syndromes and treatment location
573 predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible *Escherichia coli*
574 bloodstream infection, *Annals of clinical microbiology and antimicrobials* 19(1) (2020) 57.

575 [52] S.C. Hsueh, Y.J. Lee, Y.T. Huang, C.H. Liao, M. Tsuji, P.R. Hsueh, In vitro activities of cefiderocol,
576 ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-
577 resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, and *Stenotrophomonas*
578 *maltophilia*, all associated with bloodstream infections in Taiwan, *The Journal of antimicrobial
579 chemotherapy* 74(2) (2019) 380-386.

580 [53] M.R. Jacobs, A.M. Abdelhamed, C.E. Good, D.D. Rhoads, K.M. Hujer, A.M. Hujer, T.N.
581 Domitrovic, S.D. Rudin, S.S. Richter, D. van Duin, B.N. Kreiswirth, C. Greco, D.E. Fouts, R.A. Bonomo,
582 ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-
583 Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with
584 Defined Extended-Spectrum β -Lactamases and Carbapenemases, *Antimicrobial agents and
585 chemotherapy* 63(1) (2019).

586 [54] M.A. Hackel, M. Tsuji, Y. Yamano, R. Echols, J.A. Karlowsky, D.F. Sahm, In Vitro Activity of the
587 Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-
588 Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016, *Antimicrobial
589 agents and chemotherapy* 62(2) (2018).

590 [55] J.A. Karlowsky, M.A. Hackel, M. Tsuji, Y. Yamano, R. Echols, D.F. Sahm, In Vitro Activity of
591 Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical
592 Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015, *International journal of
593 antimicrobial agents* (2018).

594 [56] K.M. Kazmierczak, M. Tsuji, M.G. Wise, M. Hackel, Y. Yamano, R. Echols, D.F. Sahm, In vitro
595 activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant
596 carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo- β -
597 lactamase-producing isolates (SIDERO-WT-2014 Study), *International journal of antimicrobial agents*
598 53(2) (2019) 177-184.

599 [57] M.E. Falagas, T. Skolidis, K.Z. Vardakas, N.J. Legakis, Activity of cefiderocol (S-649266) against
600 carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals, *The
601 Journal of antimicrobial chemotherapy* 72(6) (2017) 1704-1708.

602 [58] M.A. Hackel, M. Tsuji, Y. Yamano, R. Echols, J.A. Karlowsky, D.F. Sahm, In Vitro Activity of the
603 Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-
604 Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates
605 (SIDERO-WT-2014 Study), *Antimicrobial agents and chemotherapy* 61(9) (2017).

606 [59] S. Kanazawa, T. Sato, N. Kohira, T. Ito-Horiyama, M. Tsuji, Y. Yamano, Susceptibility of
607 Imipenem-Susceptible but Meropenem-Resistant bla(IMP-6)-Carrying Enterobacteriaceae to Various
608 Antibacterials, Including the Siderophore Cephalosporin Cefiderocol, *Antimicrobial agents and
609 chemotherapy* 61(7) (2017).

610 [60] N. Kohira, J. West, A. Ito, T. Ito-Horiyama, R. Nakamura, T. Sato, S. Rittenhouse, M. Tsuji, Y.
611 Yamano, In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against
612 Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains, *Antimicrobial agents
613 and chemotherapy* 60(2) (2016) 729-34.

614 [61] A. Ito, N. Kohira, S.K. Bouchillon, J. West, S. Rittenhouse, H.S. Sader, P.R. Rhomberg, R.N. Jones,
615 H. Yoshizawa, R. Nakamura, M. Tsuji, Y. Yamano, In vitro antimicrobial activity of S-649266, a
616 catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-
617 negative bacteria, *J Antimicrob Chemother* 71(3) (2016) 670-7.

618 [62] B.D. Johnston, P. Thuras, S.B. Porter, C. Clabots, J.R. Johnsona, Activity of cefiderocol,
619 ceftazidime-avibactam, and eravacycline against extended-spectrum cephalosporin-resistant
620 *Escherichia coli* clinical isolates (2012-20017) in relation to phylogenetic background, sequence type
621 131 subclones, bla(CTX-M) genotype, and coresistance, *Diagnostic microbiology and infectious
622 disease* 100(1) (2021) 115314.

623 [63] B. Ihssane, E.O. Fatima, K. Aboubakr, B. Fatna, T. Mohammed, B. Pierre, H. Te-Din, N. Kaotar,
624 First report of *Pseudomonas aeruginosa* strains co-harboring bla(NDM)-bla(VIM) and bla(VIM)-
625 bla(IMP) metallo- β -lactamase genes in Morocco, *Journal of global antimicrobial resistance* 33 (2023)
626 42-43.

627 [64] P. Perez-Palacios, D. Girlich, N. Soraa, A. Lamrani, F.M.R. Maoulainine, F. Bennaoui, H. Amri, N.S.
628 El Idrissi, M. Bouskraoui, A. Birer, A.B. Jousset, S. Oueslati, J. Raymond, T. Naas, Multidrug-resistant
629 Enterobacterales responsible for septicaemia in a neonatal intensive care unit in Morocco, *Journal of
630 global antimicrobial resistance* 33 (2023) 208-217.

631 [65] S.G. Badran, M.M. Malek, R.M. Ateya, A.H. Afifi, M.M. Magdy, E.S. Elgharabawy, Susceptibility of
632 carbapenem-resistant Enterobacterales isolates to new antibiotics from a tertiary care hospital,
633 Egypt: A matter of hope, *Journal of infection in developing countries* 16(12) (2022) 1852-1859.

634 [66] M. Alzayer, M.F. Alghoribi, B. Alalwan, A. Alreheli, S. Aljohani, M. Bosaeed, M. Doumith, In vitro
635 activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative
636 bacteria from Saudi Arabia, *Journal of global antimicrobial resistance* 32 (2023) 176-180.

637 [67] Y.D. Bakthavatchalam, A. Shankar, Y. Manokaran, K. Walia, B. Veeraraghavan, Can fosfomycin be
638 an alternative therapy for infections caused by *E. coli* harbouring dual resistance: NDM and four-
639 amino acid insertion in PBP3?, *JAC-antimicrobial resistance* 5(2) (2023) dlad016.

640 [68] J.E. Cañada-García, E. Ramírez de Arellano, M. Jiménez-Orellana, E. Viedma, A. Sánchez, A.
641 Alhambra, J. Villa, A. Delgado-Iribarren, V. Bautista, N. Lara, S. García-Cobos, B. Aracil, E. Cercenado,
642 M. Pérez-Vázquez, J. Oteo-Iglesias, Carbapenemase-Producing *Klebsiella pneumoniae* in COVID-19
643 Intensive Care Patients: Identification of Incl-VIM-1 Plasmid in Previously Non-Predominant
644 Sequence Types, *Antibiotics (Basel, Switzerland)* 12(1) (2023).

645 [69] J.E. Cañada-García, Z. Moure, P.J. Sola-Campoy, M. Delgado-Valverde, M.E. Cano, D. Gijón, M.
646 González, I. Gracia-Ahufinger, N. Larrosa, X. Mulet, C. Pitart, A. Rivera, G. Bou, J. Calvo, R. Cantón, J.J.
647 González-López, L. Martínez-Martínez, F. Navarro, A. Oliver, Z.R. Palacios-Baena, Á. Pascual, G. Ruiz-
648 Carrascoso, J. Vila, B. Aracil, M. Pérez-Vázquez, J. Oteo-Iglesias, CARB-ES-19 Multicenter Study of
649 Carbapenemase-Producing *Klebsiella pneumoniae* and *Escherichia coli* From All Spanish Provinces
650 Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3, *Front
651 Microbiol* 13 (2022) 918362.

652 [70] C. Lasarte-Monterrubbio, P.A. Fraile-Ribot, J.C. Vázquez-Ucha, G. Cabot, P. Guijarro-Sánchez, I.
653 Alonso-García, S. Rumbo-Feal, F. Galán-Sánchez, A. Beceiro, J. Arca-Suárez, A. Oliver, G. Bou, Activity
654 of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against
655 ceftolozane/tazobactam- and ceftazidime/avibactam-resistant *Pseudomonas aeruginosa*, J
656 Antimicrob Chemother 77(10) (2022) 2809-2815.

657 [71] G. Morroni, L. Brescini, A. Antonelli, V. Di Pilato, S. Castelletti, A. Brenciani, G. D'Achille, M.
658 Mingoia, E. Giovanetti, S. Fioriti, A. Masucci, T. Giani, A. Giacometti, G.M. Rossolini, O. Cirioni,
659 Clinical and microbiological features of ceftolozane/tazobactam-resistant *Pseudomonas aeruginosa*
660 isolates in a university hospital in central Italy, Journal of global antimicrobial resistance 30 (2022)
661 377-383.

662 [72] P. Zalas-Więcek, K. Płachta, E. Gospodarek-Komkowska, Cefiderocol against Multi-Drug and
663 Extensively Drug-Resistant *Escherichia coli*: An In Vitro Study in Poland, Pathogens 11(12) (2022).

664 [73] L. Devoos, A. Biguenet, J. Rousselot, M. Bour, P. Plésiat, D. Fournier, K. Jeannot, Performance of
665 discs, sensititre EUMDROXF microplates and MTS gradient strips for the determination of the
666 susceptibility of multidrug-resistant *Pseudomonas aeruginosa* to cefiderocol, Clinical microbiology
667 and infection : the official publication of the European Society of Clinical Microbiology and Infectious
668 Diseases 29(5) (2023) 652.e1-652.e8.

669 [74] N. Kohira, M.A. Hackel, M. Oota, M. Takemura, F. Hu, H. Mizuno, D.F. Sahm, Y. Yamano, In vitro
670 antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in
671 2020, Journal of global antimicrobial resistance 32 (2023) 181-186.

672 [75] G. Bianco, M. Boattini, S. Comini, G. Banche, R. Cavallo, C. Costa, Disc Diffusion and ComASP(®)
673 Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in
674 Clinical Laboratory Routine, Antibiotics (Basel, Switzerland) 12(3) (2023).

675 [76] Y.S. Huang, P.Y. Chen, P.C. Chou, J.T. Wang, In Vitro Activities and Inoculum Effects of
676 Cefiderocol and Aztreonam-Avibactam against Metallo- β -Lactamase-Producing Enterobacteriaceae,
677 Microbiology spectrum 11(3) (2023) e0056923.

678 [77] C. Lasarte-Monterrubbio, P. Guijarro-Sánchez, J.C. Vázquez-Ucha, I. Alonso-García, L. Alvarez-
679 Fraga, M. Outeda, M. Martínez-Guitián, A. Peña-Escolano, R. Maceiras, E. Lence, C. González-Bello, J.
680 Arca-Suárez, G. Bou, A. Beceiro, Antimicrobial Activity of Cefiderocol against the Carbapenemase-
681 Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated
682 with Metallo- β -Lactamase VIM-1, Antimicrobial agents and chemotherapy 67(5) (2023) e0150522.

683 [78] M. Padovani, A. Bertelli, S. Corbellini, G. Piccinelli, F. Gurrieri, M.A. De Francesco, In Vitro
684 Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol
685 Resistant Strains, Antibiotics (Basel, Switzerland) 12(4) (2023).

686 [79] R.F. Potter, M.A. Wallace, C.E. Muenks, K. Alvarado, M.L. Yarbrough, C.D. Burnham, Evaluation
687 of Variability in Interpretation of Disk Diffusion Testing for Cefiderocol Using Different Brands of
688 Mueller-Hinton Agar, The journal of applied laboratory medicine 8(3) (2023) 523-534.

689 [80] P.D. Tamma, Y. Bergman, E.B. Jacobs, J.H. Lee, S. Lewis, S.E. Cosgrove, P.J. Simner, Comparing
690 the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates,
691 Infection control and hospital epidemiology 44(5) (2023) 762-767.

692 [81] V. Di Pilato, L. Henrici De Angelis, N. Aiezza, I. Baccani, C. Niccolai, E.M. Parisio, C. Giordano, G.
693 Camarlinghi, S. Barnini, S. Forni, L. Righi, M.T. Mechi, T. Giani, A. Antonelli, G.M. Rossolini, Resistome
694 and virulome accretion in an NDM-1-producing ST147 sublineage of *Klebsiella pneumoniae*
695 associated with an outbreak in Tuscany, Italy: a genotypic and phenotypic characterisation, The
696 Lancet. Microbe 3(3) (2022) e224-e234.

697 [82] L. Daoud, F. Al-Marzooq, C.A. Moubareck, A. Ghazawi, T. Collyns, Elucidating the effect of iron
698 acquisition systems in *Klebsiella pneumoniae* on susceptibility to the novel siderophore-
699 cephalosporin cefiderocol, PloS one 17(12) (2022) e0277946.

700 [83] C. Le Terrier, P. Nordmann, L. Poirel, In vitro activity of aztreonam in combination with newly
701 developed β -lactamase inhibitors against MDR Enterobacterales and *Pseudomonas aeruginosa*
702 producing metallo- β -lactamases, Journal of Antimicrobial Chemotherapy 78(1) (2022) 101-107.

703 [84] S. Maraki, V.E. Mavromanolaki, D. Stafylaki, E. Scoulica, In vitro activity of newer β -lactam/ β -
704 lactamase inhibitor combinations, cefiderocol, plazomicin and comparators against carbapenemase-
705 producing *Klebsiella pneumoniae* isolates, *Journal of chemotherapy* (Florence, Italy) (2023) 1-5.
706 [85] S. Oueslati, P. Bogaerts, L. Dortet, S. Bernabeu, H. Ben Lakhel, C. Longshaw, Y. Glupczynski, T.
707 Naas, In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative
708 Pathogens from France and Belgium, *Antibiotics* (Basel, Switzerland) 11(10) (2022).
709 [86] T. Sewunet, D. Asrat, Y. Woldeamanuel, A. Aseffa, C.G. Giske, Molecular epidemiology and
710 antimicrobial susceptibility of *Pseudomonas* spp. and *Acinetobacter* spp. from clinical samples at
711 Jimma medical center, Ethiopia, *Frontiers in microbiology* 13 (2022) 951857.
712 [87] R.A. Bonnin, C. Emeraud, A.B. Jousset, T. Naas, L. Dortet, Comparison of disk diffusion, MIC test
713 strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant
714 enterobacterales, *Clinical microbiology and infection : the official publication of the European*
715 *Society of Clinical Microbiology and Infectious Diseases* 28(8) (2022) 1156.e1-1156.e5.
716 [88] H.C. Mírza, G. İnce Ceviz, Comparison of in vitro activities of cefiderocol, imipenem/relebactam
717 and other antibiotics against carbapenem-resistant *Pseudomonas aeruginosa* isolates, *Turk Hij Den*
718 *Biyol Derg* 79(3) (2022) 433-442.
719 [89] A. Ruedas-López, I. Alonso-García, C. Lasarte-Monterrubio, P. Guijarro-Sánchez, E. Gato, J.C.
720 Vázquez-Ucha, J.A. Vallejo, P.A. Fraile-Ribot, B. Fernández-Pérez, D. Velasco, J.M. Gutiérrez-Urbón,
721 M. Oviaño, A. Beceiro, C. González-Bello, A. Oliver, J. Arca-Suárez, G. Bou, Selection of AmpC β -
722 Lactamase Variants and Metallo- β -Lactamases Leading to Ceftolozane/Tazobactam and
723 Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR *Pseudomonas aeruginosa*
724 Infections, *Antimicrob Agents Chemother* 66(2) (2022) e0206721.
725 [90] A. Iovleva, M.M. Mustapha, M.P. Griffith, L. Komarow, C. Luterbach, D.R. Evans, E. Cober, S.S.
726 Richter, K. Rydell, C.A. Arias, J.T. Jacob, R.A. Salata, M.J. Satlin, D. Wong, R.A. Bonomo, D. van Duin,
727 V.S. Cooper, D. Van Tyne, Y. Doi, Carbapenem-Resistant *Acinetobacter baumannii* in U.S. Hospitals:
728 Diversification of Circulating Lineages and Antimicrobial Resistance, *mBio* 13(2) (2022) e0275921.
729 [91] G. Nayak, B. Behera, S. Mohanty, P. Kar, J. Jena, Analysis of In Vitro Activity of Cefiderocol
730 Against Carbapenem-Resistant Gram-Negative Bacilli by Broth Microdilution and Disk Diffusion
731 Method: A Single-Center Study in Odisha, India, *Infection and drug resistance* 15 (2022) 5887-5897.
732 [92] R.A. Ramadan, A.M. Bedawy, E.M. Negm, T.H. Hassan, D.A. Ibrahim, S.M. ElSheikh, R.M. Amer,
733 Carbapenem-Resistant *Klebsiella pneumoniae* Among Patients with Ventilator-Associated
734 Pneumonia: Evaluation of Antibiotic Combinations and Susceptibility to New Antibiotics, *Infection*
735 *and drug resistance* 15 (2022) 3537-3548.
736 [93] I. Galani, V. Papoutsaki, I. Karaiskos, N. Moustakas, L. Galani, S. Maraki, V.E. Mavromanolaki, O.
737 Legga, K. Fountoulis, E.D. Platsouka, P. Giannopoulou, H. Papadogeorgaki, M. Damala, E. Chinou, A.
738 Pasxali, I. Deliolanis, H. Vagiakou, E. Petinaki, A. Chli, E. Vagdatli, P. Kazila, V. Papaioannou, K.
739 Kontopoulou, A.N. Ferke, E. Moraitou, A. Antoniadou, H. Giamarellou, In vitro activities of
740 omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against
741 *Acinetobacter baumannii* causing bloodstream infections in Greece, 2020-2021: a multicenter study,
742 *European journal of clinical microbiology & infectious diseases : official publication of the European*
743 *Society of Clinical Microbiology* 42(7) (2023) 843-852.
744 [94] M. Marner, L. Kolberg, J. Horst, N. Böhringer, J. Hübner, I.D.M. Kresna, Y. Liu, U. Mettal, L.
745 Wang, M. Meyer-Bühn, S. Mihajlovic, M. Kappler, T.F. Schäberle, U. von Both, Antimicrobial Activity
746 of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs
747 against Multidrug-Resistant *Pseudomonas aeruginosa* Isolates from Pediatric and Adolescent Cystic
748 Fibrosis Patients, *Microbiology spectrum* 11(1) (2023) e0443722.
749 [95] O.K. Ozyurt, P. Tufanoglu, O. Cetinkaya, B. Ozhak, H. Yazisiz, G. Ongut, O. Turhan, D. Ogunc, In
750 vitro Activity of Cefiderocol and Ceftazidime-Avibactam, Against Carbapenemase-Producing
751 Enterobacterales, *Clinical laboratory* 69(1) (2023).
752 [96] Karpova E.V., T. D.V., Activity of Cefiderocol and Other New Antibiotics Against Extensively Drug-
753 Resistant *Klebsiella pneumoniae* Strains. , *Antibiotics and Chemotherapy*. 67(11) (2022) 16-21.

754 [97] C. Weber, T. Schultze, S. Göttig, J. Kessel, A. Schröder, M. Tietgen, S. Besier, T. Burbach, S.
755 Häussler, T.A. Wichelhaus, D. Hack, V.A.J. Kempf, M. Hogardt, Antimicrobial Activity of Ceftolozane-
756 Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant *Pseudomonas*
757 *aeruginosa* Recovered at a German University Hospital, *Microbiology spectrum* 10(5) (2022)
758 e0169722.

759 [98] Y. Wang, Y. Li, J. Zhao, J. Guan, W. Ni, Z. Gao, Susceptibility of cefiderocol and other antibiotics
760 against carbapenem-resistant, Gram-negative bacteria, *Ann Transl Med* 10(5) (2022) 261.

761 [99] N. Kohira, M.A. Hackel, Y. Ishioka, M. Kuroiwa, D.F. Sahm, T. Sato, H. Maki, Y. Yamano, Reduced
762 susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a
763 global surveillance programme (SIDERO-WT-2014), *Journal of global antimicrobial resistance* 22
764 (2020) 738-741.

765 [100] T. Sato, A. Ito, Y. Ishioka, S. Matsumoto, M. Rokushima, K.M. Kazmierczak, M. Hackel, D.F.
766 Sahm, Y. Yamano, *Escherichia coli* strains possessing a four amino acid YRIN insertion in PBP3
767 identified as part of the SIDERO-WT-2014 surveillance study, *JAC-antimicrobial resistance* 2(3) (2020)
768 dlaa081.

769 [101] S. Stracquadiano, E. Torti, C. Longshaw, A.S. Henriksen, S. Stefani, In vitro activity of cefiderocol
770 and comparators against isolates of Gram-negative pathogens from a range of infection sources:
771 SIDERO-WT-2014-2018 studies in Italy, *Journal of global antimicrobial resistance* 25 (2021) 390-398.

772 [102] E. Cercenado, L. Cardenoso, R. Penin, C. Longshaw, A.S. Henriksen, A. Pascual, In vitro activity
773 of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range
774 of infection sources: SIDERO-WT-2014-2018 studies in Spain, *Journal of global antimicrobial*
775 *resistance* 26 (2021) 292-300.

776 [103] T. Naas, G. Lina, A. Santerre Henriksen, C. Longshaw, F. Jehl, In vitro activity of cefiderocol and
777 comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-
778 WT-2014-2018 studies in France, *JAC-antimicrobial resistance* 3(2) (2021) dlab081.

779 [104] V. Gant, A. Hussain, M. Bain, C. Longshaw, A.S. Henriksen, In vitro activity of cefiderocol and
780 comparators against Gram-negative bacterial isolates from a series of surveillance studies in
781 England: 2014-2018, *Journal of global antimicrobial resistance* 27 (2021) 1-11.

782 [105] P. Thelen, A.S. Henriksen, C. Longshaw, Y. Yamano, B. Caldwell, A. Hamprecht, In vitro activity
783 of cefiderocol against Gram-negative bacterial pathogens in Germany, *Journal of global antimicrobial*
784 *resistance* 28 (2022) 12-17.

785 [106] J.A. Karlowsky, A.J. Walkty, M.R. Baxter, H.J. Adam, P.R.S. Lagacé-Wiens, F. Schweizer, D. Bay,
786 J.P. Lynch, 3rd, M.R. Mulvey, G.G. Zhanel, In Vitro Activity of Cefiderocol against Extensively Drug-
787 Resistant *Pseudomonas aeruginosa*: CANWARD, 2007 to 2019, *Microbiology spectrum* 10(4) (2022)
788 e0172422.

789 [107] J.C. Abdul-Mutakabbir, L. Nguyen, P.T. Maassen, K.C. Stamper, R. Kebriaei, K.S. Kaye, M.
790 Castanheira, M.J. Rybak, In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant
791 *Acinetobacter baumannii*, *Antimicrob Agents Chemother* 65(9) (2021) e0264620-e0264620.

792 [108] J.A. Karlowsky, S.H. Lob, K.M. Kazmierczak, S.P. Hawser, S. Magnet, K. Young, M.R. Motyl, D.F.
793 Sahm, In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in
794 17 European countries: 2015 SMART surveillance programme, *Journal of Antimicrobial*
795 *Chemotherapy* 73(7) (2018) 1872-1879.

796 [109] K.M. Kazmierczak, P.A. Bradford, G.G. Stone, B.L.M. de Jonge, D.F. Sahm, In Vitro Activity of
797 Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae
798 Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global
799 Surveillance Program from 2012 to 2015, *Antimicrobial agents and chemotherapy* 62(12) (2018)
800 e00592-18.

801 [110] G. Bianco, P. Gaibani, S. Comini, M. Boattini, G. Banche, C. Costa, R. Cavallo, P. Nordmann,
802 Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against
803 Carbapenemase-Producing Gram-Negative Organisms, *Antibiotics (Basel, Switzerland)* 11(12) (2022).

804 [111] Y. Yamano, M. Takemura, C. Longshaw, R. Echols, 1269. Differences in Interpretative
805 Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to
806 Cefiderocol, *Open Forum Infect Dis.* 2020 Dec 31;7(Suppl 1):S651. doi: 10.1093/ofid/ofaa439.1453.
807 eCollection 2020 Oct.

808

809

810 **TABLES**

811

812 **Table 1. Univariate meta-regression analysis of the associations between study-level characteristics and prevalence of cefiderocol non-susceptible**813 **carbapenem-resistant Enterobacterales based on CLSI breakpoints.**

814

Study characteristic	Level	S	Predicted CFDC-NS % (CI)	Odds ratio (CI)	P value	R ²
Year	2015-2019	5	5.4 (0.0 - 16.3)	Ref.	0.718	0.9%
	2020-2023	31	3.6 (0.5 - 6.7)	0.66 (0.07 - 6.46)		
Region ¹	EUR	12	3.1 (0.0 - 7.2)	0.72 (0.13 - 3.88)	0.700	6.8%
	AMR	8	1.1 (0.0 - 3.3)	0.21 (0.03 - 1.63)	0.136	
	WPR	6	9.6 (0.0 - 26.2)	3.27 (0.40 - 27.02)	0.272	
	Multi-regional	10	6.1 (0.0 - 15.1)	2.05 (0.33 - 12.64)	0.440	
Multinational	No	30	4.1 (0.5 - 7.7)	Ref.	0.662	1.5%
	Yes	6	2.6 (0.0 - 7.7)	0.61 (0.07 - 5.59)		
Multicenter	No	8	27.9 (0.0 - 57.9)	Ref.	0.001	28.1%
	Yes	28	2.2 (0.3 - 4.1)	0.06 (0.01 - 0.33)		

RoB, population and setting	Moderate/High risk	33	4.3 (0.7 - 7.8)	Ref.	0.337	3.1%
	Low risk	3	1.1 (0.0 - 4.1)	0.25 (0.01 - 4.23)		
RoB, condition measurement	Moderate/High risk	19	3.8 (0.0 - 7.9)	Ref.	0.992	0.0%
	Low risk	17	3.8 (0.0 - 8.2)	1.01 (0.20 - 5.06)		

815

816 S, the number of independent data sets in the analysis; CFDC-NS, Cefiderocol non-susceptible; CI, 95% confidence interval; EUR, European region; AMR,
817 Region of the Americas; WPR, Western Pacific Region; RoB, risk of bias.

818

819 ¹ Region defined by the WHO grouping. The odds ratio for each region compares that region to all other regions combined (e.g. EUR vs.. elsewhere).

820

821 **FIGURE CAPTIONS**

822

823 **Figure 2.** Summary forest plot of cefiderocol non-susceptibility against Enterobacterales

824 **S** is the number of independent sets of data in the analysis. **n / N** is the ratio of the cumulative number of isolates that were non-susceptible to cefiderocol
825 (**CFDC-NS**) over the total number of isolates, according to the respective definition of breakpoints and resistance phenotype. The centre of the diamond is
826 the population-averaged (pooled estimate) prevalence of CFDC-NS isolates. The length of the diamond indicates the 95% confidence interval (**CI**) for the
827 pooled estimate. The horizontal thick lines extending from the diamond represent the 95% prediction interval (**PI**) for the prevalence of CFDC-NS isolates
828 in new studies. **CAR**, carbapenem; **MBL**, metallo- β -lactamase; **NDM**, New Delhi metallo- β -lactamase; **CZA**, ceftazidime/avibactam; **CTA**,
829 ceftolozane/tazobactam

830

831 **Figure 3.** Summary forest plot of cefiderocol non-susceptibility against *P. aeruginosa*

832 **S** is the number of independent sets of data in the analysis. **n / N** is the ratio of the cumulative number of isolates that were non-susceptible to Cefiderocol
833 (**CFDC-NS**) over the total number of isolates, according to the respective definition of breakpoints and resistance phenotype. The centre of the diamond is
834 the population-averaged (pooled estimate) prevalence of CFDC-NS isolates. The length of the diamond indicates the 95% confidence interval (**CI**) for the
835 pooled estimate. The horizontal thick lines extending from the diamond represent the 95% prediction interval (**PI**) for the prevalence of CFDC-NS isolates

836 in new studies. **CAR**, carbapenem; **MBL**, metallo- β -lactamase; **NDM**, New Delhi metallo- β -lactamase; **CZA**, ceftazidime/avibactam; **CTA**,
837 ceftolozane/tazobactam

838


839 **Figure 4.** Summary forest plot of cefiderocol non-susceptibility against *A. baumannii*


840 **S** is the number of independent sets of data in the analysis. **n / N** is the ratio of the cumulative number of isolates that were non-susceptible to Cefiderocol
841 (**CFDC-NS**) over the total number of isolates, according to the respective definition of breakpoints and resistance phenotype. The centre of the diamond is
842 the population-averaged (pooled estimate) prevalence of CFDC-NS isolates. The length of the diamond indicates the 95% confidence interval (**CI**) for the
843 pooled estimate. The horizontal thick lines extending from the diamond represent the 95% prediction interval (**PI**) for the prevalence of CFDC-NS isolates


844 in new studies. **CAR**, carbapenem; **MBL**, metallo- β -lactamase; **NDM**, New Delhi metallo- β -lactamase; **CZA**, ceftazidime/avibactam; **CTA**,
845 ceftolozane/tazobactam


846

847 **Figure 1. Flow chart of the review**









Supplementary material

Global prevalence of cefiderocol non-susceptibility in Enterobacterales, *P. aeruginosa*, *A. baumannii* and *S. maltophilia*: a systematic review and meta-analysis

Table of Contents

1	Breakpoints for cefiderocol by FDA, CLSI and EUCAST.....	3
2	Tool for risk of bias assessment	5
3	Characteristics of included studies.....	7
4	Summary table of study characteristics	26
5	WHO regions.....	27
6	Critical appraisal of risk of bias of reviewed studies	28
7	Overview of SIDERO-WT publications	30
8	Meta-analysis of cefiderocol non-susceptibility in Enterobacterales.....	32
8.1	Summary table.....	32
8.2	Forest plots	33
9	Meta-analysis of cefiderocol non-susceptibility in different Enterobacterales species	44
10	Meta-analysis of cefiderocol non-susceptibility in <i>P. aeruginosa</i>	46
10.1	Summary table.....	46
10.2	Forest plots	47
11	Meta-analysis of cefiderocol non-susceptibility in <i>A. baumannii</i>	65
11.1	Summary table.....	65
11.2	Forest plots	66
12	Meta-analysis of cefiderocol non-susceptibility in <i>S. maltophilia</i>	78
12.1	Summary table.....	78
12.2	Forest plots	79
13	Univariate meta-regression analyses	82
13.1	CR Enterobacterales.....	82
13.2	CR <i>K. pneumoniae</i>	83
13.3	CR <i>P. aeruginosa</i>	84
13.4	CR <i>A. baumannii</i>	85
14	References	86

Abbreviations

EUCAST	European Committee on Antimicrobial Susceptibility Testing
CAR	carbapenem
CLSI	Clinical and Laboratory Standards Institute
CTA	ceftolozane/tazobactam
CZA	ceftazidime/avibactam
MBL	metallo- β lactamase
NDM	New Delhi metallo- β lactamase,

1 Breakpoints for cefiderocol by FDA, CLSI and EUCAST

	FDA [1]				CLSI [2]				EUCAST [3]				
	MIC (mg/L)		Zone diameter in disk diffusion (mm)		MIC (mg/L)		Zone diameter in disk diffusion (mm)		MIC (mg/L)		Zone diameter in disk diffusion (mm)		
	S ≤	R >	S ≥	R <	S ≤	R >	S ≥	R <	S ≤	R >	S ≥	R <	ATU
Enterobacterales	4	8*	16	9*	4	8*	16	12*	2	2	22	22	18-22
<i>P. aeruginosa</i>	1	2*	22	13*	4	8*	18	13*	2	2	22	22	14-22
<i>A. baumannii</i>	1	2*	19	11*	4	8*	15	11*	2 [#]	2 [#]	17 [#]	ND [#]	ND
<i>S. maltophilia</i>	ND	ND	ND	ND	1	1 [§]	17	13*	2 [#]	2 [#]	20 [#]	ND [#]	ND

Abbreviations: **ATU**= area of technical uncertainty, **ND**= not defined, **R**= resistant, **S**= susceptible

* MICs or diameters between the S and R breakpoints are defined as intermediate.

Not species related PK/PD breakpoints proposed by EUCAST [3] and disk correlates [4]

§ CLSI susceptibility breakpoint for *S. maltophilia* have been recently modified to ≤1 mg/L.

In studies reporting only one set of criteria susceptibility percentages for other breakpoint criteria were inferred based on MIC distribution data when available or reported MIC ranges (when maximum MIC was below the susceptibility breakpoint a 0% non-susceptibility was inferred).

Below are 3 examples to further clarify this approach:

In the study of “Falagas ME, 2017”, the breakpoints were not defined. However, based on reported MIC ranges for *P. aeruginosa* (≤0.03–1), all *P. aeruginosa* isolates were susceptible to cefiderocol according to all three breakpoint cutoffs (CLSI, EUCAST, FDA). On the contrary, based on reported MIC ranges for *K. pneumoniae* (≤0.03–4) only susceptibility based on CLSI breakpoints (susceptible if MIC≤4mg/L) was estimable (0% non-susceptible), while susceptibility based on EUCAST breakpoints (MIC≤2mg/L) could not be estimated (>0% to 10% non-susceptible based on max MIC 4mg/L and MIC₉₀ 1mg/L). In the study “Wang Y 2022” cefiderocol susceptibility was evaluated based on CLSI breakpoints (susceptible if MIC≤4mg/L). Nevertheless, MIC ranges were also reported. For example, cefiderocol’s MIC range against CR *K. pneumoniae* was <0.03 to 2mg/L. Therefore, all CR *K. pneumoniae* isolates were also susceptible by EUCAST breakpoints (MIC≤2mg/L). On the contrary, in the study “Jacobs MR, 2018”, also applying CLSI breakpoints, the MIC range for Enterobacterales was ≤0.03 to >64mg/L and detailed MIC distribution data

were not available. Therefore, susceptibility proportion based on EUCAST breakpoints was not estimable in this study (but >10% based on MIC90 4mg/L). In other words, in studies using CLSI breakpoints and not reporting detailed MIC distribution data, cefiderocol susceptibility proportion based on EUCAST breakpoints was estimable only when 100%.

2 Tool for risk of bias assessment

Domains/items assessed	Risk of bias assessment
Domain 1: Population and setting	Low risk of bias: Answer is “Yes” to at least 3 of 4 items Moderate/high risk of bias: Answer is “No” or “Unclear” to 2 or more items
○ Were study participants sampled in an appropriate way?	Yes: Inclusion of all consecutive isolates (as eligible per study inclusion criteria) or random sample of all consecutive isolates, and exclusion of duplicates (same pathogen isolated >1 time from the same patient) No: Convenience sampling or inclusion of duplicates Unclear: Above information not clearly reported
○ Was the sample size adequate?	Yes: Study has conducted a sample size calculation. If a sample size calculation was not provided a sample size was considered adequate if >1000 for each pathogen of interest (hypothesizing a prevalence of resistance of 1% ± 0.5%) No: Study does not report any sample size calculation and sample size (for each pathogen of interest) was less than 1000.
○ Were the study subjects and the setting described in detail?	Yes: Clear description of the characteristics of the study population, including patients’ age, setting (inpatients/outpatient/mixed), type of inpatients (ICU/non-IUC/mixed), antimicrobial resistance phenotype included (any/carbapenem-resistant/MDR/XDR/PDR), origin of the infection (healthcare-onset, community-onset) No: Any of the above information missing/ not clearly reported
○ Was the data analysis conducted with sufficient coverage of the identified sample?	Yes: No missing data on susceptibility to antimicrobials of interest or missing data unlikely to introduce coverage bias No: Missing data on susceptibility to antimicrobials of interest likely to introduce coverage bias (e.g. selective rather than universal susceptibility testing to antimicrobial of interest)
Domain 2: Condition measurement (susceptibility testing method) *	Low risk of bias: Answer is “Yes” to both items Moderate/high risk of bias: Answer is “No” or “Unclear” to either of the 2 items
○ Were valid methods used for the identification of the condition?	<ul style="list-style-type: none"> • Yes: BMD in iron-depleted cation-adjusted Mueller-Hinton broth or the Sensititer lyophilized BMD panel • No: Disk diffusion or gradient strip (acceptable, but less preferable methods [5])
○ Was the condition measured in a standard, reliable way for all participants?	<ul style="list-style-type: none"> • Yes: Clear definition of how trailing (BMD) or colonies within zone (disk diffusion) were interpreted (or appropriate citations of the correct method). • No: Lack of reporting of the above
Overall risk of bias assessment	Low risk: Study at low risk of bias in both domains Moderate/high risk: Study at moderate/high risk of bias in either domain

Tool adapted from the Joann-Briggs tool for quality assessment of prevalence studies [6, 7].

BMD= broth microdilution

* Studies referencing CLSI guidelines, EUCAST guidance [8] or prior publications describing the correct methodology for assessing susceptibility of cefiderocol [9-11] were considered at low risk of bias.

3 Characteristics of included studies

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
Alzayer M, 2023 [12] set 1	Surveillance study	Saudi Arabia (NA)	2015-2019	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> <i>K. pneumoniae</i> <i>E. coli</i> CR <i>K. pneumoniae</i> CR <i>E. coli</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI, MIC distributions available CR not defined. Isolates selected based on production of VIM/NDM/KPC or OXA-48-like
Alzayer M, 2023 [12] set 2	Surveillance study	Saudi Arabia (NA)	2018-2019	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> CR <i>A. baumannii</i> CR <i>P. aeruginosa</i> 	<ul style="list-style-type: none"> MIC distributions available CR not defined
Bakthavatchalam YD, 2023 [13]	Descriptive cohort	India (1)	2020-2022	<ul style="list-style-type: none"> Moderate/high Moderate/High Moderate/high 	<ul style="list-style-type: none"> NDM <i>E.coli</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI, MIC distribution available NDM <i>E.coli</i> co-harbours a PBP3 insert
Bianco G, 2023 [14]	Descriptive cohort	Italy (3)	2019-2022	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> CP Enterobacterales CR <i>P. aeruginosa</i> CR <i>A. baumannii</i> <i>S. maltophilia</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST
Cañada-García JE, 2023 [15]	Descriptive cohort	Spain (5)	2020-2021	<ul style="list-style-type: none"> Moderate/high Moderate/High Moderate/high 	<ul style="list-style-type: none"> CP <i>K. pneumoniae</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
Galani I, 2023 [16]	Descriptive cohort	Greece (19)	2020-2021	<ul style="list-style-type: none"> Moderate/high Moderate/High Moderate/high 	<ul style="list-style-type: none"> CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI, EUCAST. Distribution of inhibition zones available. 98.9% of isolates had MEM MIC\geq4 mg/L
Devoos L, 2023 [17]	Descriptive cohort	France (78)	2015-2022	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> MDR CR <i>P. aeruginosa</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST, MIC distribution available <i>P. aeruginosa</i> resistant to ceftazidime (MIC > 8 mg/L), imipenem (MIC > 4 mg/L) and ceftolozane/tazobactam (MIC > 4/4 mg/L)
Huang YS, 2023 [18]	Descriptive cohort	Taiwan (1)	2016-2021	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> MBL-producing CR Enterobacterales 	<ul style="list-style-type: none"> Breakpoints: CLSI. EUCAST non-susceptibility estimated based on Figure 1A. CR= MEM MIC\geq4 mg/L. Dual carbapenemase isolates excluded.
Ihssane B, 2023 [19]	Surveillance study	Morocco (NA)	2021	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> MBL <i>P. aeruginosa</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST (exact MICs reported) Isolates selected based on co-harboring NDM-VIM or VIM-IMP MBLs

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> • Overall • population and setting • condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
Kohira N, 2023 [20]	Surveillance study	China (5)	2020	<ul style="list-style-type: none"> • Moderate/high • Low risk • Moderate/high 	<ul style="list-style-type: none"> • Enterobacterales • <i>P. aeruginosa</i> • <i>A. baumannii</i> • <i>S. maltophilia</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST + CLSI • CR= MEM non-susceptible based on CLSI
Lasarte-Monterrubio C, 2023 [21]	Descriptive cohort	Spain (NA)	NA	<ul style="list-style-type: none"> • Moderate/high • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • CP <i>E. cloacae</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST, MIC distribution available
Le Terrier C, 2023 [22]	Surveillance	Switzerland (NA)	NA	<ul style="list-style-type: none"> • Moderate/high • Low risk • Moderate/high 	<ul style="list-style-type: none"> • MBL Enterobacterales • MBL <i>P. aeruginosa</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST, MIC distribution available
Maraki S, 2023 [23]	Descriptive cohort	Greece (1)	2021	<ul style="list-style-type: none"> • Low risk • Low risk • Low risk 	<ul style="list-style-type: none"> • CP <i>K. pneumoniae</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST • CR= CP <i>K. pneumoniae</i>. All were also resistant to IMI and MEM.
Marner M, 2023 [24]	Descriptive cohort	Germany (1)	2006-2018	<ul style="list-style-type: none"> • Moderate/high • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • MDR <i>P. aeruginosa</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST. MIC distribution available. • MDR= resistant to the lead compounds of 3 or 4 of the following antibiotic classes: acyl ureidopenicillins (piperacillin or piperacillin-tazobactam), third- or

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> • Overall • population and setting • condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
						fourth-generation cephalosporins (ceftazidime and cefepime), fluoroquinolones (ciprofloxacin), and carbapenems (meropenem and imipenem)
Padovani M, 2023 [25]	Descriptive cohort	Italy (1)	2021-2022	<ul style="list-style-type: none"> • Moderate/high • Low risk • Moderate/high 	<ul style="list-style-type: none"> • Enterobacterales • <i>P. aeruginosa</i> • <i>A. baumannii</i> • <i>S. maltophilia</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST
Pérez-Palacios P, 2023 [26]	Descriptive cohort	Morocco (1)	2019	<ul style="list-style-type: none"> • Low risk • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • MDR Enterobacterales (all <i>K. pneumoniae</i> or <i>E. hormaechei</i>) 	<ul style="list-style-type: none"> • Breakpoints: EUCAST. • MDR= “resistance to at least three families of antibiotics compared to the wild-type phenotype” • CR if MEM MIC>8mg/L
Potter RF, 2023 [27]	Descriptive cohort	USA (1)	2018-2020	<ul style="list-style-type: none"> • Moderate/high • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • Enterobacterales • <i>P. aeruginosa</i> • <i>A. baumannii</i> • <i>S. maltophilia</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI, EUCAST, FDA

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> • Overall • population and setting • condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
Ruedas-López A, 2023 [28]	Descriptive cohort	Spain (1)	2020	<ul style="list-style-type: none"> • Low risk • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • CTA-resistant, CZA-resistant <i>P. aeruginosa</i> 	<ul style="list-style-type: none"> • Breakpoints: MIC distribution available.
Sewunet T, 2023 [29]	Descriptive cohort	Ethiopia (1)	2016	<ul style="list-style-type: none"> • Low risk • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • CZA/MEM-resistant <i>P. aeruginosa</i> • CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST • CR= MEM MIC>8mg/L
Tamma PD, 2023 [30]	Descriptive cohort	USA (3)	2016-2021	<ul style="list-style-type: none"> • Moderate/high • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • CR Enterobacterales 	<ul style="list-style-type: none"> • Breakpoints: CLSI • CR= resistant to at least 1 carbapenem or carrying at least 1 carbapenemase gene
Xu J, 2023 [31]	Descriptive cohort	China (1)	2016-2017	<ul style="list-style-type: none"> • Moderate/high • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • NDM CR <i>E. coli</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI, MIC distribution available
Badran SG, 2022 [32]	Descriptive cohort	Egypt (1)	2021	<ul style="list-style-type: none"> • Moderate/high • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • CR Enterobacterales • MBL Enterobacterales 	<ul style="list-style-type: none"> • Breakpoints: CLSI (only resistance proportion reported, non-susceptibility data not available) • CR defined as resistance (by disk diffusion) to any of MEM, IMP, DOR, ETP
Ballesté-Delpierre C, 2022 [33]	Surveillance study	Argentina, Azerbaijan,	NA	<ul style="list-style-type: none"> • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • <i>A. baumannii</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI, MIC distribution available

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
		Croatia, Greece, Italy, Morocco, Mozambique, Peru, Spain (NA)		<ul style="list-style-type: none"> Moderate/high 		<ul style="list-style-type: none"> CR defined as MEM MIC>8 mg/L
Bonnin RA, 2022 [5]	Descriptive cohort	France (NA)	2021	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> CR Enterobacterales 	<ul style="list-style-type: none"> Breakpoints: EUCAST, MIC distribution available CR= MEM>8mg/L
Cañada-García JE, 2022 [34]	Descriptive cohort	Spain (62)	2019-2019	<ul style="list-style-type: none"> Moderate/high Moderate/High Moderate/high 	<ul style="list-style-type: none"> CP <i>E. coli</i> and <i>K. pneumoniae</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST
Candel FJ, 2022 [35]	Surveillance study (SIDERO-WT*)	Europe (145)	2013-2018	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> Enterobacterales <i>P. aeruginosa</i> <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST CR defined as MEM MIC>8 mg/L
Di Pilato V, 2022 [36]	Descriptive cohort	Italy (11)	2018-2019	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> NDM-1 producing <i>K. pneumoniae</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST, MIC distribution available
Daoud L, 2022[37]	Descriptive cohort	United Arab Emirates (3)	NA	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> <i>K. pneumoniae</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI, MIC distribution available CR= MEM MIC>8mg/L
Iovleva A, 2022 [38]	Descriptive cohort	USA (23)	2017-2018	<ul style="list-style-type: none"> Low risk Moderate/high Moderate/high 	<ul style="list-style-type: none"> CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI CR= MEM or IMI MIC ≥4mg/L
Karlowsky JA, 2022 [39]	Surveillance study	USA, Canada, Europe (205)	2014-2019	<ul style="list-style-type: none"> Low risk Low risk 	<ul style="list-style-type: none"> Enterobacterales <i>P. aeruginosa</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI, MIC distribution available

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
	(SIDERO-WT*)			<ul style="list-style-type: none"> Low risk 	<ul style="list-style-type: none"> <i>A. baumannii</i> <i>S. maltophilia</i> 	<ul style="list-style-type: none"> MEM-nonsusceptible (MIC \geq 2 mg/L)
Karlowsky JA, 2022 [40]	Surveillance study (CANWARD)	Canada (NA)	2007	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> MDR/XDR <i>P. aeruginosa</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI, MIC distribution available MDR/XDR or not susceptible to any of the antipseudomonal agents tested. CR=meronem non-susceptible by CLSI 2022
Karpova EV, 2022 [41]	Descriptive cohort	Russia	2016-2021	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> XDR <i>K. pneumoniae</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST
Lan P, 2022 [42]	Descriptive cohort	China (15)	2018-2020	<ul style="list-style-type: none"> Low risk Low risk Low risk 	<ul style="list-style-type: none"> CR <i>K. pneumoniae</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI, MIC distribution available CR not defined
Lasarte-Monterrubio C, 2022 [43]	Descriptive cohort	Spain (3)	NA	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> CZA-R and CTA-R <i>P. aeruginosa</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST, MIC distribution available CZA-R and CTA-R <i>P. aeruginosa</i> following cephalosporin treatment

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
Mirza HC, 2022 [44]	Descriptive cohort	Turkey (1)	2014-2018	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> <i>CR P. aeruginosa</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST and CLSI CR= IMI-resistant by CLSI and EUCAST
Morroni G, 2022 [45]	Descriptive cohort	Italy (1)	2018-2019	<ul style="list-style-type: none"> Low risk Low risk Low risk 	<ul style="list-style-type: none"> CTA-R <i>P. aeruginosa</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST, MIC distribution available
Nayak G, 2022 [46]	Descriptive cohort	India (1)	2020-2021	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> CR Enterobacterales CR <i>P. aeruginosa</i> CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI, MICI distribution available CR= resistance to any carbapenem (MEM, IMI, ETP, DOR)
Ramadan RA, 2022 [47]	Descriptive cohort	Egypt (1)	2020-2021	<ul style="list-style-type: none"> Low risk Moderate/high Moderate/high 	<ul style="list-style-type: none"> CR <i>K. pneumoniae</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI CR= non-susceptibility to at least one carbapenem (MEM, IMI, ETP, DOR)
Oueslati S, 2022 [48]	Surveillance study	France, Belgium (NA)	2012-2019	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> CR Enterobacterales CR <i>P. aeruginosa</i> CR <i>A. baumannii</i> <i>S. maltophilia</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST, MIC distribution available CR= carbapenemase-producing or CR by other mechanisms (but CR not-defined)

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
Shortridge D, 2022 [49]	Surveillance study (SENTRY)	Europe (35), USA (31)	2020	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> Enterobacterales <i>P. aeruginosa</i> <i>A. baumannii</i> <i>S. maltophilia</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI, EUCAST, FDA. CR defined as MEM/IMP MIC>2mg/L
Wang Q, 2022 [50]	Surveillance study (China CRE-Network)	China (48)	2018-2019	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> CR <i>E. coli</i> CR <i>K. pneumoniae</i> CR <i>Enterobacter cloacae</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI CR defined as resistance to at least 1 carbapenem or at least 1 carbapenemase production
Wang Y, 2022 [51]	Descriptive cohort	China (4)	2012-2018	<ul style="list-style-type: none"> Low risk Low risk Low risk 	<ul style="list-style-type: none"> CR <i>K. pneumoniae</i> CR <i>P. aeruginosa</i> CR <i>A. baumannii</i> <i>S. maltophilia</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI All isolates had MEM and IMP MIC ≥8mg/L
Weber C, 2022 [52]	Descriptive cohort	Germany (1)	2013-2017	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> CR <i>P. aeruginosa</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST CR= MDR nonsusceptible for at least piperacillin-tazobactam, ceftazidime, cefepime, imipenem, meropenem, and ciprofloxacin. Species
Zalas-Więcek P, 2022 [53]	Descriptive cohort	Poland (2)	2016-2022	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> MDR <i>E. coli</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST, MIC distribution available

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
Zhang Q, 2022 [54]	Descriptive cohort	USA (14)	2011-2018	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> CR Enterobacterales 	<ul style="list-style-type: none"> Breakpoints: CLSI, MIC distribution available CR defined as NS to at least 1 carbapenem (based on CLSI breakpoints)
Abdul-Mutakabbir JC, 2021 [55]	Surveillance study	USA (1)	NA	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI CR not defined (all isolates had MEM MIC >4mg/L)
Albano M, 2021 [56]	Surveillance studies	USA, Canada, Singapore (NA)	NA	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> Enterobacterales <i>P. aeruginosa</i> <i>A. baumannii</i> <i>S. maltophilia</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI, MIC distribution available Isolates selected for cefiderocol-resistance were excluded
Bhagwat SS, 2021 [57]	Surveillance study	Greece (15)	2014-2018	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> Enterobacterales <i>P. aeruginosa</i> <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST, FDA CR defined as MEM MIC >8 mg/L and IMP MIC >4 mg/L
Carcione D, 2021 [58]	Surveillance study	Italy (1)	2020-2021	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: EUCAST, MIC distribution available 17 of 20 isolates had MEM MIC >8mg/ml. Included only in the

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> • Overall • population and setting • condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
						CR/CNS/CP subgroup meta-analysis
Choby JE, 2021 [59]	Surveillance study (Georgia EIP)	USA (NA)	Different ranges per pathogen	<ul style="list-style-type: none"> • Moderate/high • Moderate/high • Moderate high 	<ul style="list-style-type: none"> • CR <i>Klebsiella</i> spp (2011-2015) • CR <i>P. aeruginosa</i> (2015-2016) • CR <i>A. baumannii</i> (2012-2015) • <i>S. maltophilia</i> (2018-2021) 	<ul style="list-style-type: none"> • Breakpoints: CLSI • CR not defined
Ghebremedhin B, 2021 [60]	Surveillance studies	Germany (1)	2014-2021	<ul style="list-style-type: none"> • Moderate/high • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • CR Enterobacterales • CR <i>P. aeruginosa</i> • CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST, MIC distribution available • CR not defined
Jacob A, 2021 [61]	Descriptive cohort	Belgium (1)	2015-2020	<ul style="list-style-type: none"> • Moderate/high • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • Enterobacterales 	<ul style="list-style-type: none"> • Breakpoints: EUCAST, CLSI, FDA • Selected for OXA-427 production
Johnston BD, 2021, [62]	Descriptive cohort	USA (1)	2012-2017	<ul style="list-style-type: none"> • Moderate/high • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • ESBL <i>E. coli</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST, MIC distribution data available
Lee YL, 2021 [63]	Surveillance (SMART)	Taiwan (16)	2017-2020	<ul style="list-style-type: none"> • Moderate/high • Low risk • Moderate/high 	<ul style="list-style-type: none"> • <i>E. coli</i> • <i>K. pneumoniae</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI, MIC distribution available • For the CR subgroup in the meta-analysis only

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> • Overall • population and setting • condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
						the CP isolates were considered
Liu PY, 2021 [64]	Surveillance study (SMART)	Taiwan (16)	2018-2020	<ul style="list-style-type: none"> • Moderate/high • Low • Moderate/high 	<ul style="list-style-type: none"> • CR <i>P. aeruginosa</i> • CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI • IMP MIC >2 mg/dl
Morris CP, 2021 [4]	Descriptive cohort	USA (1)	2017	<ul style="list-style-type: none"> • Moderate/high • Low • Moderate/high 	<ul style="list-style-type: none"> • CR Enterobacterales • CR <i>P. aeruginosa</i> • CR <i>A. baumannii</i> • <i>S. maltophilia</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI, EUCAST • ETP MIC \geq 2mg/dl for Enterobacterales • MEM MIC \geq 8mg/dl for <i>P. aeruginosa</i> and <i>A. baumannii</i>.
Biagi M, 2020 [65]	Surveillance study (SENTRY)	Multinational (detailed data not available)	2017-2018	<ul style="list-style-type: none"> • Moderate/high • Low • Moderate/high 	<ul style="list-style-type: none"> • <i>S. maltophilia</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI
Delgado-Valverde, 2020 [66]	Surveillance (PIRASOA programme)	Spain (27)	2014-2018	<ul style="list-style-type: none"> • Moderate/high • Low • Moderate/high 	<ul style="list-style-type: none"> • CP <i>K. pneumoniae</i> • CP <i>E. cloacae</i> • CP <i>P. aeruginosa</i> • CP-<i>A. baumannii</i> • <i>S. maltophilia</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI • ESBL and/or CP isolates selected. 112 of 125 Enterobacterales, all <i>A. baumannii</i> and all <i>P. aeruginosa</i> were CP
Golden RA, 2020 [67]	Surveillance study (CANWARD)	Canada (14)	2015-2017	<ul style="list-style-type: none"> • Moderate/high • Low risk • Moderate/high 	<ul style="list-style-type: none"> • Enterobacterales • <i>P. aeruginosa</i> • <i>A. baumannii</i> • <i>S. maltophilia</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI, MIC distribution available • CR Enterobacterales and <i>P. aeruginosa</i> defined based on

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> • Overall • population and setting • condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
						ertapenem- and meropenem non-susceptibility, respectively
Iregui A, 2020 [68], set 1	Surveillance study	USA (7)	2017	<ul style="list-style-type: none"> • Moderate/high • Low • Moderate/high 	<ul style="list-style-type: none"> • <i>E. coli</i> • <i>Enterobacter</i> spp • <i>K. pneumoniae</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI (“S” if MIC≤4mg/L)
Iregui A, 2020 [68], set 2	Surveillance study	USA (7)	2013-2014	<ul style="list-style-type: none"> • Moderate/high • Low • Moderate/high 	<ul style="list-style-type: none"> • CR <i>K. pneumoniae</i> • CR <i>P. aeruginosa</i> • CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI (“S” if MIC≤4mg/L) • CR not defined
Iregui A, 2020 [68], set 3	Descriptive cohort	USA (NA)	NA	<ul style="list-style-type: none"> • Moderate/high • Low • Moderate/high 	<ul style="list-style-type: none"> • <i>K. pneumoniae</i> • <i>P. aeruginosa</i> • <i>A. baumannii</i> 	<ul style="list-style-type: none"> • Breakpoints: CLSI (“S” if MIC≤4mg/L). MIC distribution data available. • Isolates well-characterized for presence of b-lactamase and porin/efflux resistance mechanisms
Johnston BD, 2020 [69]	Surveillance study (MDH, SENTRY)	USA, China, India, Taiwan, Philippines, Thailand, Korea, Vietnam, Turkey,	MDH 2009-2017 SENTRY 2003-2017	<ul style="list-style-type: none"> • Moderate/high • Moderate/high • Moderate/high 	<ul style="list-style-type: none"> • CR <i>E. coli</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST • “non-susceptible to ≥ 1 carbapenems” (CLSI M100-S27 cited)

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> • Overall • population and setting • condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
		Italy, Russia, Spain, UK, Israel, Belarus, Belgium, Germany, Greece, Poland, Chile, Argentina, Brazil, Mexico, Ecuador, Venezuela. (NA)				
Kresken M, 2020 [70], set 1	Surveillance study (Paul-Ehrlich society)	Germany (12)	2013-2014	<ul style="list-style-type: none"> • Low risk • Low risk • Low risk 	<ul style="list-style-type: none"> • Enterobacterales • <i>P. aeruginosa</i> • <i>A. baumannii</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST, MIC distribution available
Kresken M, 2020 [70], set 2	Surveillance studies	Germany	2010-2017	<ul style="list-style-type: none"> • Moderate/high • Low risk • Moderate/high 	<ul style="list-style-type: none"> • CP Enterobacterales • CP <i>P. aeruginosa</i> • CP <i>A. baumannii</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST, MIC distribution available • Isolates selected for carbapenemase production
Longshaw C, 2020 [71]	Surveillance study (SIDERO-CR)	Europe (110); predominantly Italy, Greece, Russia	2014-2016	<ul style="list-style-type: none"> • Moderate/high • Low risk • Moderate/high 	<ul style="list-style-type: none"> • CP Enterobacterales • CP <i>P. aeruginosa</i> • CP <i>A. baumannii</i> 	<ul style="list-style-type: none"> • Breakpoints: EUCAST, MIC distribution available • CR defined as MEM MIC ≥ 2mg/L. Overlap with Hackel MA, 2018 [72].

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
						Useful for MBL data + for EUCAST breakpoints
Mushtaq S, 2020 [73]	Surveillance study (PHE-AMRHAI)	United Kingdom (NA)	2008-2018	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> CR Enterobacterales CR <i>P. aeruginosa</i> CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI, FDA, EUCAST CR not defined. Isolates selected based on carbapenemase production or CR associated with other mechanisms
Rolston KVI, 2020 [74]		USA (1)	2014-2017	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> Enterobacterales (including ESBL and CR subgroups) MDR <i>P. aeruginosa</i> <i>A. baumannii</i> <i>S. maltophilia</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI (“S” if MIC≤4mg/L), MIC distribution data available CR and MDR not defined
Talan DA, 2020 [75]	Descriptive cohort	USA (11)	2018-2019	<ul style="list-style-type: none"> Low risk Moderate/high Moderate/high 	<ul style="list-style-type: none"> Enterobacterales 	<ul style="list-style-type: none"> Breakpoints: CLSI ESBL
Trebosc V, 2020 [76]	Surveillance study (JMI laboratories)	Europe (144), USA (99), Asia-West Pacific (50)	2017-2019	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI CR not defined (all isolates had MEM MIC>8mg/L)
Xie O, 2020 [77]	Descriptive cohort	Australia (1)	2015-2016	<ul style="list-style-type: none"> Low risk Moderate/high Moderate/high 	<ul style="list-style-type: none"> <i>E. coli</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI ceftriaxone-non-susceptible

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
Hsueh SC, 2019 [78]	Descriptive cohort	Taiwan (1)	2016-2017	<ul style="list-style-type: none"> Moderate/high Low Moderate/high 	<ul style="list-style-type: none"> CR <i>P. aeruginosa</i> CR <i>A. baumannii</i> <i>S. maltophilia</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI ("S" if MIC≤4mg/L) IMP MIC ≥ 8mg/dl
Jacobs MR, 2018 [79]	Surveillance (ARGONAUT)	USA (NA)	NA	<ul style="list-style-type: none"> Moderate/high Low Moderate/high 	<ul style="list-style-type: none"> Enterobacteriales <i>P. aeruginosa</i> <i>A. baumannii</i> <i>S. maltophilia</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI ("S" if MIC≤4mg/L) Carbapenem-resistance defined as MEM MIC>1mg/L for Enterobacteriales, >2mg/L for <i>Acinetobacter</i> and <i>Pseudomonas</i>
Hackel MA, 2018 [72]	Surveillance study (IHMA)	24 countries in Europe, 10 countries in Latin America, 2 countries in North America, 8 countries in Asia, 3 countries in South Pacific, 2 countries in Africa, 3 countries in Middle East. (NA)	2014-2016	<ul style="list-style-type: none"> Moderate/high Low Moderate/high 	<ul style="list-style-type: none"> CR Enterobacteriales CR <i>P. aeruginosa</i> CR <i>A. baumannii</i> <i>S. maltophilia</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI ("S" if MIC≤4mg/L) MEM MIC ≥ 2mg/dl for Enterobacteriales MEM MIC ≥ 16 mg/dl for <i>P. aeruginosa</i> and <i>A. baumannii</i>.
Karlowsky JA, 2018 [10], set 1	Surveillance study	North America (45); USA, Canada	2015-2016	<ul style="list-style-type: none"> Moderate/high Low risk 	<ul style="list-style-type: none"> <i>Klebsiella</i> spp <i>E. coli</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
	(SIDERO-WT*)			<ul style="list-style-type: none"> Moderate/high 	<ul style="list-style-type: none"> Serratia spp Enterobacter spp Citrobacter spp 	
Karlowsky JA, 2018 [10], set 2	Surveillance study (SIDERO-WT*)	Europe (55)	2015-2016	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> Klebsiella spp E. coli Serratia spp Enterobacter spp Citrobacter spp 	<ul style="list-style-type: none"> Breakpoints: CLSI
Kazmierczak KM 2018 [80]	Surveillance study (SIDERO-WT*)	Canada, United States, Czech Republic, France, Germany, Greece, Hungary, Italy, Russia, Spain, Sweden, Turkey, United Kingdom (99 hospitals total)	2014	<ul style="list-style-type: none"> Moderate/high Low Moderate/high 	<ul style="list-style-type: none"> MBL Enterobacteriales MBL <i>P. aeruginosa</i> MBL <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: CLSI ("S" if MIC≤4mg/L) Data extracted only for MBL producers*
Falagas ME, 2017 [81]	Descriptive cohort	Greece (18)	2010-2016	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> CR <i>K. pneumoniae</i> CR <i>E. cloacae</i> CR <i>P. stuartii</i> CR <i>P. aeruginosa</i> CR <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: not defined. MIC range, MIC₅₀ and MIC₉₀ reported. MEM MIC >1mg/dl for Enterobacteriales MEM MIC > 2mg/dl for <i>P. aeruginosa</i> and <i>A. baumannii</i>

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
Hackel MA, 2017 [11], set 1	Surveillance study (SIDERO-WT*)	North America (50); USA, Canada	2014-2015	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> Klebsiella spp E. coli Serratia spp Enterobacter spp Citrobacter spp 	<ul style="list-style-type: none"> Breakpoints: CLSI
Hackel MA, 2017 [11], set 2	Surveillance study (SIDERO-WT*)	Europe (49)	2014-2015	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> Klebsiella spp E. coli Serratia spp Enterobacter spp Citrobacter spp 	<ul style="list-style-type: none"> Breakpoints: CLSI
Kanazawa S, 2017 [82]	Surveillance study	Japan (1)	2010-2014	<ul style="list-style-type: none"> Moderate/high Low risk Moderate/high 	<ul style="list-style-type: none"> Enterobacterales 	<ul style="list-style-type: none"> Breakpoints: CLSI, MIC distribution available IMP-Susceptible (≤ 1mg/L) but MEM-Resistant (≥ 4mg/L) blaIMP-6
Ito A, 2016 [83], set 1	Descriptive cohort	Worldwide (NA)	2009-2011	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> <i>P. aeruginosa</i> <i>A. baumannii</i> <i>S. maltophilia</i> 	<ul style="list-style-type: none"> Breakpoints: Not defined. MIC distribution data available
Ito A, 2016 [83], set 2	Descriptive cohort	Worldwide (NA)	2000-2009	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> <i>P. aeruginosa</i> <i>A. baumannii</i> 	<ul style="list-style-type: none"> Breakpoints: Not defined. MIC distribution data available “β-lactam-resistant” isolates

First author, publication year	Study type	Countries (number of institutions)	Period of isolate collection	Risk of bias assessment: <ul style="list-style-type: none"> Overall population and setting condition measurement 	Susceptibility data for;	Breakpoints used by the study, availability of MIC distribution data and definition of resistance phenotypes of included isolates
Kohira N, 2016 [84], set 1	Surveillance study (IHMA)	North America, Europe, Africa, Asia, Latin America, South Pacific, Middle East (NA)	2009-2011	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> <i>E. coli</i> <i>K pneumoniae</i> <i>S marcescens</i> <i>C freundii</i> <i>E aerogenes</i> <i>E cloacae</i> 	<ul style="list-style-type: none"> Breakpoints: Not defined CR defined as meropenem MIC>4
Kohira N, 2016 [84], set 2	Surveillance study (JMI Laboratories)	North America, Europe, Asia-Pacific, and Latin America (NA)	2000-2009	<ul style="list-style-type: none"> Moderate/high Moderate/high Moderate/high 	<ul style="list-style-type: none"> <i>K pneumoniae</i> <i>S marcescens</i> <i>C freundii</i> <i>E cloacae</i> 	<ul style="list-style-type: none"> Breakpoints: Not defined, MIC distribution available Well-characterized for β-lactamases

Abbreviations: ARGONAUT= Antibacterial Resistance Leadership Group [ARLG] Reference Group for the testing of Novel Therapeutics, CP= carbapenemase-producing, CR= carbapenem-resistant (including carbapenem-nonsusceptible), DOR= doripenem EIP= Emerging Infections Program, ESBL= extended-spectrum β -lactamase, ETP= ertapenem, IHMA= International Health Management Associates, IMP= imipenem, MBL= metallo- β -lactamase producing, MDH= Minnesota Department of Health, MEM= meropenem, MIC= minimum inhibitory concentration, NA= not available, NS= non-susceptible, PHE-AMRHAI= Public Health England's Antimicrobial Resistance and Healthcare Associated Infections, PIRASOA= Institutional Programme for the Prevention and Control of Healthcare-Associated Infections and Appropriate Use of Antimicrobials (Andalusia), RCT= randomized controlled trial, SMART= Surveillance of Multicenter Antimicrobial Resistance in Taiwan

* See prior Table for data extracted from each SIDERO-WT publication

4 Summary table of study characteristics

Variable	Statistics ^{1,2}
Year of publication	
2015-2019	10 (13%)
2020-2023	68 (87%)
Region	
Europe	34 (40%)
Americas	18 (21%)
Western Pacific region	11 (13%)
Other region	10 (11%)
Multiple regions	13 (15%)
Multinational study	20 (24%)
Median number of countries (IQR)	1 (1-1)
Multicentre study	59 (69%)
Median number of hospitals (IQR)	4.5 (1-19)
Age group of patients	
Adults	5 (6%)
All ages	8 (9%)
Pediatric	1 (1%)
Not reported	72 (84%)
Type of patients	
Inpatients	12 (14%)
Outpatients	1 (1%)
Mixed	8 (9%)
Not reported	65 (76%)
Broth microdilution for CFDC susceptibility test	72 (84%)
MIC distribution reported	38 (44%)
Population and setting risk of bias	
Low	12 (14%)
Moderate-to-high	74 (86%)
Condition measurement risk of bias	
Low	40 (47%)
Moderate-to-high	46 (53%)
Overall risk of bias	
Low	5 (6%)
Moderate-to-high	81 (94%)

CFDC= cefiderocol

¹ Summary statistics are median (interquartile range) for continuous variables, and n (%) for categorical variables.

² 78 publications contributed 86 independent sets of data. Summary statistics for all variables, except the year of publication, were calculated over the 86 independent sets of data.

5 WHO regions

WHO-regions		Number of independent study sets*	%
Americas		28	33%
	Only in America	18	26%
	As part of multi-regional study	10**	12%
European region		43	50%
	Only in Europe	34	28%
	As part of multi-regional study	9**	11%
Western Pacific region		15	17%
	Only in Western Pacific region	11	13%
	As part of multi-regional study	4	5%
South-East Asia region		6	7%
	Only in South-East Asia region	2	2%
	As part of multi-regional study	4	5%
Africa		4	5%
	Only in Africa	1	1%
	As part of multi-regional study	3	4%
Eastern Mediterranean region		10	12%
	Only in Eastern Mediterranean region	7	8%
	As part of multi-regional study	3	4%
Not reported (multiple regions)		3	4%
Multiregional		13 **	15%

* n=78 studies contributing to n=86 independent data sets

**Including n=3 AMR, EUR, n=1 AMR, WPR, n=1 AMR, EUR, WPR, n=1 AMR, EUR, WPR, SEAR, n=1 AMR, EUR, EMR, AFR, n=1 AMR, UR, EMR, SEAR, n=1 AMR, EUR, EMR, SEAR, AFR, n=1 AMR, EUR, WPR, AFR, SEAR, n=3 multiple regions but regions not specified n=3

6 Critical appraisal of risk of bias of reviewed studies

Study	Q1	Q2	Q3	Q4	Q5	Q6	PS	CM	Overall
Abdul-Mutakabbir JC, 2021	U	N	N	Y	Y	Y	MH	L	MH
Albano M (excl IHMA set), 2021	U	N	N	Y	Y	Y	MH	L	MH
Alzayer M, set 1, 2023	Y	N	N	Y	Y	N	MH	MH	MH
Alzayer M, set2, 2023	Y	N	N	Y	Y	N	MH	MH	MH
Badran SG, 2022	U	N	Y	Y	N	N	MH	MH	MH
Bakthavatchalam YD, 2023	U	N	N	Y	N	N	MH	MH	MH
Ballesté-Delpierre C, 2022	U	N	N	N	Y	N	MH	MH	MH
Bhagwat SS, 2021	Y	N	N	Y	Y	N	MH	MH	MH
Biagi M, 2020	U	N	N	Y	Y	Y	MH	L	MH
Bianco G, 2023	U	N	N	Y	Y	Y	MH	L	MH
Bonnin RA, 2022	U	N	N	Y	Y	N	MH	MH	MH
Candel FJ, 2022	Y	N	N	Y	Y	Y	MH	L	MH
Carcione D, 2021	U	N	N	Y	Y	N	MH	MH	MH
Cañada-García JE, 2022	Y	N	N	Y	N	N	MH	MH	MH
Cañada-García JE, 2023	Y	N	N	Y	N	N	MH	MH	MH
Choby JE, 2021	U	N	N	Y	N	Y	MH	MH	MH
Daoud L, 2022	U	N	N	Y	Y	N	MH	MH	MH
Delgado-Valverde M, 2020	U	N	N	Y	Y	Y	MH	L	MH
Devoos L, 2023	U	N	N	Y	Y	Y	MH	L	MH
Di Pilato V, 2022	N	N	Y	Y	N	N	MH	MH	MH
Falagas ME, 2017	Y	N	N	Y	Y	N	MH	MH	MH
Galani I, 2023	Y	N	N	Y	N	N	MH	MH	MH
Ghebremedhin B, 2021	U	N	N	Y	N	N	MH	MH	MH
Golden RA, 2020	U	N	N	Y	Y	Y	MH	L	MH
Hackel MA, 2018	U	N	N	Y	Y	Y	MH	L	MH
Hackel MA, Europe, 2017	U	N	N	Y	Y	Y	MH	L	MH
Hackel MA, North America, 2017	U	N	N	Y	Y	Y	MH	L	MH
Hsueh SC, 2019	U	N	N	Y	Y	Y	MH	L	MH
Huang YS, 2023	Y	N	N	Y	Y	Y	MH	L	MH
Ihssane B, 2023	U	N	N	Y	Y	N	MH	MH	MH
Iovleva A, 2022	Y	N	Y	Y	Y	N	L	MH	MH
Iregui A, set 1, 2020	U	N	N	Y	Y	Y	MH	L	MH
Iregui A, set 2, 2020	U	N	N	Y	Y	Y	MH	L	MH
Iregui A, set 3, 2020	N	N	N	Y	Y	Y	MH	L	MH
Ito A, set 1, 2015	Y	N	N	Y	N	N	MH	MH	MH
Ito A, set 2, 2015	Y	N	N	Y	N	N	MH	MH	MH
Jacob A, 2021	Y	N	N	Y	Y	N	MH	MH	MH
Jacobs MR, 2018	U	N	N	Y	Y	Y	MH	L	MH
Johnston BD, 2020	U	N	N	Y	Y	N	MH	MH	MH
Johnston BD, 2021	Y	N	N	Y	Y	N	MH	MH	MH
Kanazawa S, 2017	U	N	N	Y	Y	Y	MH	L	MH
Karlow sky JA (1), 2022	Y	N	N	Y	Y	Y	MH	L	MH
Karlow sky JA (2), 2022	Y	N	N	Y	Y	Y	MH	L	MH
Karlow sky JA, Europe, 2018	Y	N	N	Y	Y	Y	MH	L	MH
Karlow sky JA, North America, 2018	Y	N	N	Y	Y	Y	MH	L	MH
Karpova EV, 2022	U	N	N	Y	Y	N	MH	MH	MH
Kazmierczak KM, 2019	U	N	N	Y	Y	Y	MH	L	MH
Kohira N, 2023	U	N	N	Y	Y	Y	MH	L	MH
Kohira N, set 1, 2016	Y	N	N	Y	N	N	MH	MH	MH
Kohira N, set 2, 2016	U	N	N	Y	N	N	MH	MH	MH

Kresken M, set 1, 2020	Y	N	Y	Y	Y	Y	L	L	L
Kresken M, set 2, 2020	Y	N	N	Y	Y	Y	MH	L	MH
Lan P, 2022	Y	N	Y	Y	Y	Y	L	L	L
Lasarte-Monterrubio C, 2022	U	N	Y	Y	Y	N	MH	MH	MH
Lasarte-Monterrubio C, 2023	U	N	N	Y	Y	N	MH	MH	MH
Le Terrier C, 2023	U	N	N	Y	Y	Y	MH	L	MH
Lee YL, 2021	U	N	N	Y	Y	Y	MH	L	MH
Liu PY, 2021	U	N	N	Y	Y	Y	MH	L	MH
Longshaw C, 2020	U	N	N	Y	Y	Y	MH	L	MH
Maraki S, 2023	Y	N	Y	Y	Y	Y	L	L	L
Marner M, 2023	U	N	Y	Y	N	Y	MH	MH	MH
Morris CP, 2021	Y	N	N	Y	Y	Y	MH	L	MH
Morrioni G, 2022	Y	N	Y	Y	Y	Y	L	L	L
Mushtaq S, 2020	Y	N	N	Y	Y	N	MH	MH	MH
Mirza HC, 2022	Y	N	N	Y	N	N	MH	MH	MH
Nayak G, 2022	Y	N	N	Y	Y	Y	MH	L	MH
Oueslati S, 2022	U	N	N	Y	Y	Y	MH	L	MH
Ozyurt OK, 2023	U	N	N	Y	N	N	MH	MH	MH
Padovani M, 2023	Y	N	N	Y	Y	Y	MH	L	MH
Potter RF, 2023	U	N	N	Y	Y	N	MH	MH	MH
Pérez-Palacios P, 2023	Y	N	Y	Y	Y	N	L	MH	MH
Ramadan RA, 2022	Y	N	Y	Y	N	N	L	MH	MH
Rolston KVI, 2020	U	N	N	Y	Y	N	MH	MH	MH
Ruedas-López A, 2023	Y	N	Y	Y	Y	N	L	MH	MH
Sewunet T, 2023	Y	N	Y	Y	N	N	L	MH	MH
Shortridge D, 2022	Y	N	N	Y	Y	Y	MH	L	MH
Talan DA, 2020	Y	N	Y	Y	N	N	L	MH	MH
Tamma PD, 2023	Y	N	N	Y	Y	N	MH	MH	MH
Trebosc V, 2020	U	N	N	Y	Y	N	MH	MH	MH
Wang Q, 2022	U	N	N	Y	Y	Y	MH	L	MH
Wang Y, 2022	Y	N	Y	Y	Y	Y	L	L	L
Weber C, 2022	U	N	N	Y	N	N	MH	MH	MH
Xie O, 2020	Y	N	Y	Y	N	N	L	MH	MH
Xu J, 2023	Y	N	N	N	Y	N	MH	MH	MH
Zalas-Więcek P, 2022	U	N	N	Y	N	N	MH	MH	MH
Zhang Q, 2022	U	N	N	Y	Y	N	MH	MH	MH

Notes.

PS, population and setting domain; **CM**, condition measurement domain, **Y/U/N**, yes/unclear/no; **L**; low risk of bias; **MH**, moderate-to-high risk of bias.

Q1: Were study participants sampled in an appropriate way?

Q2: Was the sample size adequate?

Q3: Were the study subjects and the setting described in detail?

Q4: Was the data analysis conducted with sufficient coverage of the identified sample?

Q5: Were valid methods used for the identification of the condition?

Q6: Was the condition measured in a standard, reliable way for all participants?

7 Overview of SIDERO-WT publications

First author, publication year	Study period	Countries-isolates involved	Notes regarding overlap	Included/ excluded in the meta-analysis
Karlowksy, 2022 [39]	2014-2019	Total* all isolates	Overlap with all prior SIDERO-WT publications (but no separate data for different Enterobacterales spp)	Included
Candel FJ, 2022 [35]	2014-2019	Europe all isolates	Overlap with Karlowksy 2022 but additional data for each Enterobacterales spp and from SIDERO-Proteeae	Included in meta-analyses for specific Enterobacterales spp (EUCAST breakpoints)
Thelen P, 2022 [85]	2014-2018	Germany all isolates	Overlap with Karlowksy 2022, Candel 2022, Karlowksy 2018 and Hackel 2017	Excluded
Stracquadanio S, 2021 [86]	2014-2018	Italy all isolates	Overlap with Karlowksy 2022, Candel 2022, Karlowksy 2018 and Hackel 2017	Excluded
Cercenado E, 2021 [87]	2014-2018	Spain all isolates	Overlap with Karlowksy 2022, Candel 2022, Karlowksy 2018 and Hackel 2017	Excluded
Naas T, 2021 [88]	2014-2018	France all isolates	Overlap with Karlowksy 2022, Candel 2022, Karlowksy 2018 and Hackel 2017	Excluded
Gant V, 2021 [89]	2014-2018	England all isolates	Overlap with Karlowksy 2022, Candel 2022, Karlowksy 2018 and Hackel 2017	Excluded
Karlowksy et al 2018 [10]	2015-2016	Total* all isolates	Overlap with Karlowksy	Included in meta-analyses for specific Enterobacterales spp (CLSI breakpoints)
Sato T, 2020 [90]	2014	Total* E. coli isolates with four	Selection of isolates from SIDERO-WT 2014	Excluded

		aminoacid insertion in PBP-3		
Kohira et al 2020 [91]	2014	Total* isolates with cefiderocol MIC>4 mg/L	Subgroup of isolates from SIDERO- WT 2014	Excluded (no data of interest for meta- analysis)
Kazmierczak KM 2018 [80]	2014	Total* carbapenem NS isolates	Subgroup of isolates from SIDERO- WT 2014	Included for meta- analysis of MBL- producers subgroups.
Hackel MA, 2017 [11]	2014-2015	Total*- all isolates	Subgroups of isolates reported in Kazmierczak 2018 and Kohira 2020)	Included in meta- analyses for specific Enterobacterales spp (CLSI breakpoints)

Abbreviations: MIC= minimum inhibitory concentration, NS= non-susceptible

* USA, Canada, Europe (Austria, Belgium, Croatia, Czech Republic, Denmark, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom)

8 Meta-analysis of cefiderocol non-susceptibility in Enterobacterales


8.1 Summary table

Enterobacterales	Breakpoints	S	n/N	CFDC -NS %	Lower CL, %	Upper CL, %	I ² , %	τ ²	Lower PL, %	Upper PL, %
Any phenotype	CLSI-FDA	23	287/47545	0.9	0.3	2.2	92	4.305	0.0	42.9
	EUCAST	20	906/47065	3.0	1.5	6.0	98	2.561	0.1	49.1
CR	CLSI-FDA	36	537/7175	3.8	1.7	8.4	10	6.827	0.0	89.5
	EUCAST	34	975/5589	12.4	7.3	20.0	99	2.646	0.5	80.3
MBL-producing	CLSI-FDA	24	279/1679	13.0	7.3	22.3	93	2.047	0.7	75.9
	EUCAST	25	443/1507	24.9	16.6	35.5	95	1.347	2.8	79.5
NDM-producing	CLSI-FDA	22	380/1476	18.7	10.6	31.0	96	2.099	1.0	83.6
	EUCAST	20	534/1024	38.8	22.6	58.0	99	2.778	1.7	95.8
CZA-resistant	CLSI-FDA	5	46/557	8.3	6.2	10.9	0	0.000	5.2	12.8
	EUCAST	5	66/165	36.6	22.7	53.1	83	0.345	6.2	83.4
CTA-resistant	CLSI-FDA	3	73/1125	10.6	2.4	36.8	96	1.816	0.0	100.0
	EUCAST	1	3/30

S is the number of independent datasets in the analysis (a single study may have contributed more than one sets of data). n/N is the ratio of the cumulative number of Enterobacterales isolates that were non-susceptible to Cefiderocol (CFDC-NS) over the total number of isolates, according to the respective definition of breakpoints and resistance phenotype. CFDC-NS, cefiderocol non-susceptible; CL, 95% confidence limit; PL, 95% prediction limit; CAR, carbapenem; MBL, metallo-β-lactamase; NDM, New Delhi metallo-β-lactamase; CZA, ceftazidime/avibactam; CTA, ceftolozane/tazobactam


8.2 Forest plots

8.2.1 Enterobacterales, any phenotype; CLSI-FDA




Note. n is the number of Enterobacterales (any phenotype) isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI-FDA breakpoints. N is the overall number of Enterobacterales (any phenotype) clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

8.2.2 Enterobacterales, any phenotype; EUCAST




Note. n is the number of Enterobacterales (any phenotype) isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of Enterobacterales (any phenotype) clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

8.2.3 Enterobacterales, carbapenem-resistant; CLSI-FDA




Note. n is the number of CR Enterobacterales isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI-FDA breakpoints. N is the overall number of CR Enterobacterales clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

8.2.4 Enterobacterales, carbapenem-resistant; EUCAST




Note. n is the number of CR Enterobacterales isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of CR Enterobacterales clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

8.2.5 Enterobacterales, MBL-producing; CLSI-FDA




Note. n is the number of MBL-producing Enterobacterales isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI-FDA breakpoints. N is the overall number of MBL-producing Enterobacterales clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

8.2.6 Enterobacterales, MBL-producing; EUCAST




Note. n is the number of MBL-producing Enterobacterales isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of MBL-producing Enterobacterales clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

8.2.7 Enterobacterales, NDM-producing; CLSI-FDA




Note. n is the number of NDM-producing Enterobacterales isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI-FDA breakpoints. N is the overall number of NDM-producing Enterobacterales clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

8.2.8 Enterobacterales, NDM-producing; EUCAST




Note. n is the number of NDM-producing Enterobacterales isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of NDM-producing Enterobacterales clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

8.2.9 Enterobacterales, CZA-resistant; CLSI-FDA




Note. n is the number of CZA-resistant Enterobacterales isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI-FDA breakpoints. N is the overall number of CZA-resistant Enterobacterales clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

8.2.10 Enterobacterales, CZA-resistant; EUCAST



Note. n is the number of CZA-resistant Enterobacterales isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of CZA-resistant Enterobacterales clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

8.2.11 Enterobacterales, CTA-resistant; CLSI-FDA



Note. n is the number of CTA-resistant Enterobacterales isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI-FDA breakpoints. N is the overall number of CTA-resistant Enterobacterales clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

9 Meta-analysis of cefiderocol non-susceptibility in different Enterobacterales species

Klebsiella spp.	Breakpoints	S	n/N	CFDC-NS %	Lower CL, %	Upper CL, %	I², %	τ²	Lower PL, %	Upper PL, %
Any phenotype	CLSI-FDA	20	47/6121	0.1	0.0	0.9	66	10.769	0.0	64.0
	EUCAST	13	286/6600	2.7	1.0	7.0	96	2.731	0.1	55.5
CR	CLSI-FDA	24	131/3320	1.8	0.7	4.3	86	3.843	0.0	54.0
	EUCAST	20	379/2114	10.6	5.2	20.3	96	2.524	0.4	78.7
MBL-producing	CLSI-FDA	11	34/269	4.1	1.1	14.4	85	2.878	0.1	72.9
	EUCAST	11	54/272	8.9	2.6	26.4	92	3.273	0.1	88.4
E. coli										
Any phenotype	CLSI-FDA	16	32/6658	0.3	0.1	1.2	56	6.897	0.0	50.1
	EUCAST	13	79/7498	1.0	0.3	3.6	85	5.584	0.0	69.0
CR	CLSI-FDA	15	107/763	4.3	1.3	12.8	90	2.930	0.1	69.2
	EUCAST	15	147/793	10.8	4.8	22.9	91	1.863	0.5	73.1
MBL-producing	CLSI-FDA	9	62/233	14.0	3.4	42.8	96	4.185	0.1	96.6
	EUCAST	9	96/231	36.3	15.3	64.3	96	2.588	1.0	97.0
Enterobacter spp.										
Any phenotype	CLSI-FDA	14	16/2620	0.3	0.1	1.7	21	5.712	0.0	45.2
	EUCAST	9	66/1644	3.0	0.6	12.9	86	3.802	0.0	81.9
CR	CLSI-FDA	15	44/626	6.5	3.2	12.8	70	0.940	0.7	39.8
	EUCAST	11	51/233	22.6	15.6	31.6	66	0.173	9.0	46.2
MBL-producing	CLSI-FDA	7	22/152	15.7	3.9	45.9	85	3.027	0.1	96.1
	EUCAST	6	28/108	30.6	16.6	49.4	78	0.310	6.1	74.9
Proteus spp.										
Any phenotype	CLSI-FDA	3	2/66	3.0	0.8	11.3	0	0.000	0.1	40.7
	EUCAST	4	6/664	2.1	0.2	16.1	0	4.234	0.0	97.4
CR	CLSI-FDA	3	1/25	4.0	0.6	23.5	0	0.000	0.0	100.0
	EUCAST	2	0/17	0.0	.	.	0	0.542	.	.

Serratia spp.	Breakpoints	S	n/N	CFDC-NS %	Lower CL, %	Upper CL, %	I², %	τ²	Lower PL, %	Upper PL, %
Any phenotype	CLSI-FDA	10	10/2009	0.4	0.1	1.6	0	2.701	0.0	19.4
	EUCAST	7	10/1851	0.5	0.3	1.0	15	0.000	0.2	1.2
CR	CLSI-FDA	1	5/5
	EUCAST	3	3/16	18.8	6.2	44.8	15	0.000	1.4	78.4
Citrobacter spp.										
Any phenotype	CLSI-FDA	9	5/1160	0.4	0.2	1.0	0	0.000	0.1	1.2
	EUCAST	4	11/899	1.9	0.5	6.6	0	0.441	0.0	52.0
Morganella spp.										
Any phenotype	CLSI-FDA	3	0/24	0.0	.	.	0	0.542	.	.
	EUCAST	4	0/302	0.0	.	.	0	1.000	.	.

S is the number of independent datasets in the analysis (a single study may have contributed more than one sets of data). **n/N** is the ratio of the cumulative number of *Klebsiella* spp. isolates that were non-susceptible to Cefiderocol (**CFDC-NS**) over the total number of isolates, according to the respective definition of breakpoints and resistance phenotype. **CFDC-NS**, cefiderocol non-susceptible; **CL**, 95% confidence limit; **PL**, 95% prediction limit; **CAR**, carbapenem; **MBL**, metallo-β-lactamase; **NDM**, New Delhi metallo-β-lactamase; **CZA**, ceftazidime/avibactam; **CTA**, ceftolozane/tazobactam

10 Meta-analysis of cefiderocol non-susceptibility in *P. aeruginosa*


10.1 Summary table

<i>P. aeruginosa</i>	Breakpoints	S	n/N	CFDC-NS %	Lower CL, %	Upper CL, %	I ² , %	τ ²	Lower PL, %	Upper PL, %
Any phenotype	CLSI	14	38/9975	0.3	0.1	1.3	63	4.638	0.0	29.2
	EUCAST	15	174/11991	1.4	0.5	4.0	89	2.986	0.0	41.9
	FDA	11	487/11710	3.3	1.4	7.7	97	1.639	0.2	42.7
CR	CLSI	23	68/4389	0.8	0.3	2.2	64	3.361	0.0	30.4
	EUCAST	20	218/4041	3.5	1.6	7.8	91	2.849	0.1	58.8
	FDA	16	500/3653	14.6	7.5	26.3	97	1.954	0.8	79.2
MBL-producing	CLSI	13	22/562	1.6	0.3	7.8	53	5.045	0.0	74.9
	EUCAST	12	32/527	1.8	0.3	10.4	74	8.010	0.0	92.8
	FDA	9	72/381	23.3	10.4	44.1	92	1.854	1.1	89.5
NDM-producing	CLSI	6	8/41	19.5	10.1	34.4	2	0.000	8.1	40.0
	EUCAST	7	14/51	22.9	8.1	49.7	67	1.339	1.2	88.0
	FDA	6	25/41	58.7	20.4	88.7	90	3.413	0.7	99.6
CZA-resistant	CLSI	7	22/1163	1.7	0.5	5.1	73	1.682	0.0	39.9
	EUCAST	5	54/519	6.8	3.1	14.6	87	0.505	0.5	50.8
	FDA	5	122/519	19.5	11.9	30.4	90	0.315	3.1	64.8
CTA-resistant	CLSI	8	20/1038	2.2	0.8	5.6	59	1.322	0.1	32.3
	EUCAST	6	41/376	8.3	4.1	16.0	75	0.432	1.1	42.7
	FDA	6	81/376	15.1	7.4	28.2	90	0.678	1.4	69.4

S is the number of independent datasets in the analysis (a single study may have contributed more than one sets of data). **n/N** is the ratio of the cumulative number of *Klebsiella* spp. isolates that were non-susceptible to Cefiderocol (**CFDC-NS**) over the total number of isolates, according to the respective definition of breakpoints and resistance phenotype. **CFDC-NS**, cefiderocol non-susceptible; **CL**, 95% confidence limit; **PL**, 95% prediction limit; **CAR**, carbapenem; **MBL**, metallo-β-lactamase; **NDM**, New Delhi metallo-β-lactamase; **CZA**, ceftazidime/avibactam; **CTA**, ceftolozane/tazobactam


10.2 Forest plots

10.2.1 *P. aeruginosa*, any phenotype; CLSI




Note. n is the number of *P. aeruginosa* (any phenotype) isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI breakpoints. N is the overall number of *P. aeruginosa* (any phenotype) clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.2 *P. aeruginosa*, any phenotype; EUCAST




Note. n is the number of *P. aeruginosa* (any phenotype) isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of *P. aeruginosa* (any phenotype) clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.3 *P. aeruginosa*, any phenotype; FDA




Note. n is the number of *P. aeruginosa* (any phenotype) isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to FDA breakpoints. N is the overall number of *P. aeruginosa* (any phenotype) clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.4 *P. aeruginosa*, carbapenem-resistant; CLSI




Note. n is the number of CR *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI breakpoints. N is the overall number of CR *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.5 *P. aeruginosa*, carbapenem-resistant; EUCAST




Note. n is the number of CR *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of CR *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.6 *P. aeruginosa*, carbapenem-resistant; FDA




Note. n is the number of CR *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to FDA breakpoints. N is the overall number of CR *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.7 *P. aeruginosa*, MBL-producing; CLSI




Note. n is the number of MBL-producing *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI breakpoints. N is the overall number of MBL-producing *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.8 *P. aeruginosa*, MBL-producing; EUCAST




Note. n is the number of MBL-producing *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of MBL-producing *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.9 *P. aeruginosa*, MBL-producing; FDA




Note. n is the number of MBL-producing *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to FDA breakpoints. N is the overall number of MBL-producing *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.10 *P. aeruginosa*, NDM-producing; CLSI




Note. n is the number of NDM-producing *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI breakpoints. N is the overall number of NDM-producing *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.11 *P. aeruginosa*, NDM-producing; EUCAST




Note. n is the number of NDM-producing *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of NDM-producing *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.12 *P. aeruginosa*, NDM-producing; FDA




Note. n is the number of NDM-producing *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to FDA breakpoints. N is the overall number of NDM-producing *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.13 *P. aeruginosa*, CZA-resistant; CLSI




Note. n is the number of CZA-resistant *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI breakpoints. N is the overall number of CZA-resistant *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.14 *P. aeruginosa*, CZA-resistant; EUCAST




Note. n is the number of CZA-resistant *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of CZA-resistant *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.15 *P. aeruginosa*, CZA-resistant; FDA




Note. n is the number of CZA-resistant *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to FDA breakpoints. N is the overall number of CZA-resistant *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.




Note. n is the number of CTA-resistant *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI breakpoints. N is the overall number of CTA-resistant *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

10.2.17 *P. aeruginosa*, CTA-resistant; EUCAST



Note. n is the number of CTA-resistant *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of CTA-resistant *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.



Note. n is the number of CTA-resistant *P. aeruginosa* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to FDA breakpoints. N is the overall number of CTA-resistant *P. aeruginosa* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11 Meta-analysis of cefiderocol non-susceptibility in *A. baumannii*


11.1 Summary table

<i>A. baumannii</i>	Breakpoints	S	n/N	CFDC-NS %	Lower CL, %	Upper CL, %	I ² , %	τ ²	Lower PL, %	Upper PL, %
Any phenotype	CLSI	14	278/6888	3.8	1.9	7.4	86	1.183	0.3	32.5
	EUCAST	13	422/6658	8.8	4.9	15.2	85	0.882	1.1	46.2
	FDA	12	725/6656	15.0	8.4	25.3	92	1.025	1.6	65.4
CR	CLSI	27	487/6047	8.5	5.7	12.5	91	1.027	1.1	44.1
	EUCAST	20	535/4831	13.2	7.8	21.5	95	1.524	1.0	68.7
	FDA	14	792/4171	26.6	18.3	36.9	95	0.698	5.1	70.7
MBL-producing	CLSI	9	19/93	20.4	13.4	29.8	58	0.000	12.3	32.0
	EUCAST	9	38/93	40.9	31.4	51.1	65	0.000	29.6	53.2
	FDA	9	61/93	53.1	21.5	82.4	86	2.953	1.4	98.9
NDM-producing	CLSI	8	19/85	23.0	13.6	36.3	67	0.146	8.0	50.7
	EUCAST	8	38/85	44.7	34.5	55.4	71	0.000	32.2	58.0
	FDA	8	60/85	71.3	21.7	95.7	90	8.076	0.1	100.0

S is the number of independent datasets in the analysis (a single study may have contributed more than one sets of data). **n/N** is the ratio of the cumulative number of *Klebsiella* spp. isolates that were non-susceptible to Cefiderocol (**CFDC-NS**) over the total number of isolates, according to the respective definition of breakpoints and resistance phenotype. **CFDC-NS**, cefiderocol non-susceptible; **CL**, 95% confidence limit; **PL**, 95% prediction limit; **CAR**, carbapenem; **MBL**, metallo-β-lactamase; **NDM**, New Delhi metallo-β-lactamase; **CZA**, ceftazidime/avibactam; **CTA**, ceftolozane/tazobactam


11.2 Forest plots

11.2.1 *A. baumannii*, any phenotype; CLSI




Note. n is the number of *A. baumannii* (any phenotype) isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI breakpoints. N is the overall number of *A. baumannii* (any phenotype) clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11.2.2 *A. baumannii*, any phenotype; EUCAST




Note. n is the number of *A. baumannii* (any phenotype) isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of *A. baumannii* (any phenotype) clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11.2.3 *A. baumannii*, any phenotype; FDA




Note. n is the number of *A. baumannii* (any phenotype) isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to FDA breakpoints. N is the overall number of *A. baumannii* (any phenotype) clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11.2.4 *A. baumannii*, carbapenem-resistant; CLSI




Note. n is the number of CR *A. baumannii* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI breakpoints. N is the overall number of CR *A. baumannii* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11.2.5 *A. baumannii*, carbapenem-resistant; EUCAST




Note. n is the number of CR *A. baumannii* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of CR *A. baumannii* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11.2.6 *A. baumannii*, carbapenem-resistant; FDA




Note. n is the number of CR *A. baumannii* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to FDA breakpoints. N is the overall number of CR *A. baumannii* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11.2.7 *A. baumannii*, MBL-producing; CLSI




Note. n is the number of MBL-producing *A. baumannii* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI breakpoints. N is the overall number of MBL-producing *A. baumannii* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11.2.8 *A. baumannii*, MBL-producing; EUCAST




Note. n is the number of MBL-producing *A. baumannii* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of MBL-producing *A. baumannii* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11.2.9 *A. baumannii*, MBL-producing; FDA




Note. n is the number of MBL-producing *A. baumannii* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to FDA breakpoints. N is the overall number of MBL-producing *A. baumannii* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11.2.10 *A. baumannii*, NDM-producing; CLSI




Note. n is the number of NDM-producing *A. baumannii* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI breakpoints. N is the overall number of NDM-producing *A. baumannii* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11.2.11 *A. baumannii*, NDM-producing; EUCAST



Note. n is the number of NDM-producing *A. baumannii* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of NDM-producing *A. baumannii* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

11.2.12 *A. baumannii*, NDM-producing; FDA



Note. n is the number of NDM-producing *A. baumannii* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to FDA breakpoints. N is the overall number of NDM-producing *A. baumannii* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

12 Meta-analysis of cefiderocol non-susceptibility in *S. maltophilia*


12.1 Summary table

<i>S. maltophilia</i>	Breakpoints	S	n/N	CFDC-NS %	Lower CL, %	Upper CL, %	I ² , %	τ ²	Lower PL, %	Upper PL, %
	CLSI old	19	5/3289	0.2	0.1	0.4	0	0.000	0.1	0.4
	CLSI new	13	81/3003	0.1	0.0	3.7	96	21.388	0.0	98.2
	EUCAST	15	11/3030	0.4	0.2	0.7	0	0.000	0.2	0.7

S is the number of independent datasets in the analysis (a single study may have contributed more than one sets of data). **n/N** is the ratio of the cumulative number of *Klebsiella* spp. isolates that were non-susceptible to Cefiderocol (**CFDC-NS**) over the total number of isolates, according to the respective definition of breakpoints and resistance phenotype. **CFDC-NS**, cefiderocol non-susceptible; **CL**, 95% confidence limit; **PL**, 95% prediction limit; **CAR**, carbapenem; **MBL**, metallo-β-lactamase; **NDM**, New Delhi metallo-β-lactamase; **CZA**, ceftazidime/avibactam; **CTA**, ceftolozane/tazobactam


12.2 Forest plots

12.2.1 Previous CLSI breakpoints




Note. n is the number of *S. maltophilia* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI old breakpoints. N is the overall number of *S. maltophilia* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

12.2.2 New CLSI breakpoints



Note. n is the number of *S. maltophilia* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to CLSI new breakpoints. N is the overall number of *S. maltophilia* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

12.2.3 EUCAST breakpoints



Note. n is the number of *S. maltophilia* isolates that were non-susceptible to Cefiderocol (CFDC-NS) according to EUCAST breakpoints. N is the overall number of *S. maltophilia* clinical isolates in the study. The diamond's center is the population-averaged percentage (pooled estimate) of CFDC-NS isolates. The diamond's length and the respective grey vertical area indicate the 95% confidence interval of the pooled estimate. The extended line continuing through the confidence interval represents the 95% prediction interval of the percentage of CFDC-NS isolates expected in new studies.

13 Univariate meta-regression analyses

13.1 CR Enterobacterales

Study characteristic	Level	S	Predicted CFDC-NS % (CI)	Odds ratio (CI)	P-value	R ²
Year	2015-2019	5	5.4 (0.0 - 16.3)	Ref.	0.718	0.9%
	2020-2023	31	3.6 (0.5 - 6.7)	0.66 (0.07 - 6.46)		
Region ¹	EUR	12	3.1 (0.0 - 7.2)	0.72 (0.13 - 3.88)	0.700	6.8%
	AMR	8	1.1 (0.0 - 3.3)	0.21 (0.03 - 1.63)	0.136	
	WPR	6	9.6 (0.0 - 26.2)	3.27 (0.40 - 27.02)	0.272	
	Multi-regional	10	6.1 (0.0 - 15.1)	2.05 (0.33 - 12.64)	0.440	
Multinational	No	30	4.1 (0.5 - 7.7)	Ref.	0.662	1.5%
	Yes	6	2.6 (0.0 - 7.7)	0.61 (0.07 - 5.59)		
Multicenter	No	8	27.9 (0.0 - 57.9)	Ref.	0.001	28.1%
	Yes	28	2.2 (0.3 - 4.1)	0.06 (0.01 - 0.33)		
RoB, population and setting	Moderate/High risk	33	4.3 (0.7 - 7.8)	Ref.	0.337	3.1%
	Low risk	3	1.1 (0.0 - 4.1)	0.25 (0.01 - 4.23)		
RoB, condition measurement	Moderate/High risk	19	3.8 (0.0 - 7.9)	Ref.	0.992	0.0%
	Low risk	17	3.8 (0.0 - 8.2)	1.01 (0.20 - 5.06)		

Univariate meta-regression analysis of the associations between study-level characteristics and prevalence of Cefiderocol non-susceptible CR Enterobacterales based on CLSI-FDA breakpoints.

S, the number of independent data sets in the analysis; **CFDC-NS**, Cefiderocol non-susceptible; **CI**, 95% confidence interval; **EUR**, European region; **AMR**, Region of the Americas; **WPR**, Western Pacific Region; **RoB**, risk of bias.

¹ Region defined by the WHO grouping. The odds ratio for each region compares that region to all other regions combined (e.g. EUR vs. elsewhere).

13.2 CR *K. pneumoniae*

Study characteristic	Level	S	Predicted CFDC-NS % (CI)	Odds ratio (CI)	P-value	R ²
Year	2015-2019	4	0.2 (0.0 - 0.8)	Ref.	0.101	13.2%
	2020-2023	19	2.4 (0.1 - 4.8)	11.42 (0.62 - 209.44)		
Region ¹	EUR	8	0.9 (0.0 - 2.3)	0.36 (0.05 - 2.38)	0.287	23.9%
	AMR	5	2.8 (0.0 - 8.3)	1.92 (0.21 - 17.35)	0.560	
	WPR	3	0.5 (0.0 - 1.7)	0.23 (0.02 - 2.93)	0.258	
	Multi-regional	7	4.3 (0.0 - 10.8)	3.77 (0.58 - 24.67)	0.165	
Multinational	No	20	2.0 (0.0 - 3.9)	Ref.	0.384	3.5%
	Yes	3	0.5 (0.0 - 1.9)	0.23 (0.01 - 6.26)		
Multicenter	No	5	4.7 (0.0 - 12.8)	Ref.	0.204	7.5%
	Yes	18	1.3 (0.0 - 2.6)	0.26 (0.03 - 2.08)		
RoB, population and setting	Moderate/High risk	20	1.8 (0.0 - 3.6)	Ref.	0.840	0.6%
	Low risk	3	1.3 (0.0 - 4.6)	0.77 (0.06 - 10.27)		
RoB, condition measurement	Moderate/High risk	13	2.3 (0.0 - 5.1)	Ref.	0.462	4.6%
	Low risk	10	1.2 (0.0 - 2.8)	0.51 (0.08 - 3.09)		

Univariate meta-regression analysis of the associations between study-level characteristics and prevalence of Cefiderocol non-susceptible CR *K. pneumoniae* based on CLSI breakpoints.

S, the number of independent data sets in the analysis; **CFDC-NS**, Cefiderocol non-susceptible; **CI**, 95% confidence interval; **EUR**, European region; **AMR**, Region of the Americas; **WPR**, Western Pacific Region; **RoB**, risk of bias.

¹ Region defined by the WHO grouping. The odds ratio for each region compares that region to all other regions combined (e.g. EUR vs. elsewhere).

13.3 CR *P. aeruginosa*

Study characteristic	Level	S	Predicted CFDC-NS % (CI)	Odds ratio (CI)	P-value	R ²
Year	2015-2019	5	0.6 (0.0 - 1.8)	Ref.	0.739	2.0%
	2020-2023	18	0.9 (0.0 - 1.9)	1.43 (0.17 - 12.01)		
Region ¹	EUR	9	1.1 (0.0 - 2.9)	1.59 (0.26 - 9.60)	0.613	18.8%
	AMR	5	0.5 (0.0 - 1.7)	0.60 (0.06 - 5.99)	0.661	
	WPR	4	0.1 (0.0 - 0.4)	0.07 (0.00 - 1.48)	0.089	
	Multi-regional	5	2.0 (0.0 - 5.2)	3.61 (0.46 - 28.51)	0.223	
Multinational	No	19	1.0 (0.0 - 2.1)	Ref.	0.552	8.4%
	Yes	4	0.5 (0.0 - 1.5)	0.52 (0.06 - 4.41)		
Multicenter	No	5	1.2 (0.0 - 3.4)	Ref.	0.618	0.0%
	Yes	18	0.7 (0.0 - 1.6)	0.59 (0.08 - 4.66)		
RoB, population and setting	Moderate/High risk	22	0.9 (0.0 - 1.8)	Ref.	.	4.5%
	Low risk	1	Insufficient data	Non-estimable		
RoB, condition measurement	Moderate/High risk	8	1.0 (0.0 - 2.5)	Ref.	0.784	1.6%
	Low risk	15	0.8 (0.0 - 1.7)	0.77 (0.12 - 4.87)		

Univariate meta-regression analysis of the associations between study-level characteristics and prevalence of Cefiderocol non-susceptible CR *P. aeruginosa* based on CLSI breakpoints).

S, the number of independent data sets in the analysis; **CFDC-NS**, Cefiderocol non-susceptible; **CI**, 95% confidence interval; **EUR**, European region; **AMR**, Region of the Americas; **WPR**, Western Pacific Region; **RoB**, risk of bias.

¹ Region defined by the WHO grouping. The odds ratio for each region compares that region to all other regions combined (e.g. EUR vs. elsewhere).

13.4 CR *A. baumannii*

Study characteristic	Level	S	Predicted CFDC-NS % (CI)	Odds ratio (CI)	P-value	R ²
Year	2015-2019	4	5.0 (0.0 - 10.2)	Ref.	0.298	4.1%
	2020-2023	22	9.0 (5.2 - 12.8)	1.86 (0.58 - 6.01)		
Region ¹	EUR	9	7.7 (2.0 - 13.4)	0.90 (0.35 - 2.34)	0.836	0.0%
	AMR	6	8.5 (1.6 - 15.5)	1.06 (0.38 - 2.94)	0.907	
	WPR	4	8.2 (0.3 - 16.2)	1.01 (0.32 - 3.18)	0.991	
	Multi-regional	7	8.4 (2.3 - 14.5)	1.04 (0.41 - 2.68)	0.929	
Multinational	No	20	7.6 (4.0 - 11.2)	Ref.	0.556	0.0%
	Yes	6	9.9 (2.5 - 17.4)	1.34 (0.50 - 3.56)		
Multicenter	No	5	18.8 (5.5 - 32.1)	Ref.	0.020	20.6%
	Yes	21	6.7 (3.9 - 9.5)	0.31 (0.12 - 0.83)		
RoB, population and setting	Moderate/High risk	23	7.8 (4.6 - 11.0)	Ref.	0.401	6.3%
	Low risk	3	13.3 (0.0 - 28.6)	1.82 (0.45 - 7.31)		
RoB, condition measurement	Moderate/High risk	10	8.7 (3.2 - 14.2)	Ref.	0.798	0.4%
	Low risk	16	7.9 (3.8 - 11.9)	0.89 (0.37 - 2.15)		

Univariate meta-regression analysis of the associations between study-level characteristics and prevalence of Cefiderocol non-susceptible CR *A. baumannii* based on CLSI breakpoints.

S, the number of independent data sets in the analysis; **CFDC-NS**, Cefiderocol non-susceptible; **CI**, 95% confidence interval; **EUR**, European region; **AMR**, Region of the Americas; **WPR**, Western Pacific Region; **RoB**, risk of bias.

¹ Region defined by the WHO grouping. The odds ratio for each region compares that region to all other regions combined (e.g. EUR vs. elsewhere).

14 References

- [1] FDA, Cefiderocol Injection. FDA Identified Breakpoints. <<https://www.fda.gov/drugs/development-resources/cefiderocol-injection>>, 2020 (accessed 22/12/2022.2022).
- [2] CLSI, Performance Standards for Antimicrobial Susceptibility Testing. 32st ed. CLSI supplement M100., Clinical Laboratory Standards Institute, Wayne, 2022.
- [3] The European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0. <<http://www.eucast.org/>>, 2023 (accessed 2023-03-24.2023).
- [4] C.P. Morris, Y. Bergman, T. Tekle, J.A. Fissel, P.D. Tamma, P.J. Simner, Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison of Disk Diffusion to Broth Microdilution, *Journal of clinical microbiology* 59(1) (2020).
- [5] R.A. Bonnin, C. Emeraud, A.B. Jousset, T. Naas, L. Dortet, Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales, *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 28(8) (2022) 1156.e1-1156.e5.
- [6] C.B. Migliavaca, C. Stein, V. Colpani, Z. Munn, M. Falavigna, Quality assessment of prevalence studies: a systematic review, *Journal of clinical epidemiology* 127 (2020) 59-68.
- [7] Z. Munn, S. Moola, K. Lisy, D. Riitano, C. Tufanaru, Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data, *International journal of evidence-based healthcare* 13(3) (2015) 147-53.
- [8] European Society for Clinical Microbiology and Infectious Diseases, Guidance document on broth microdilution testing of cefiderocol. <https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Cefiderocol_MIC_testing_EUCAST_guidance_document_201217.pdf>, 2020 (accessed February 2022.).
- [9] M.A. Hackel, M. Tsuji, Y. Yamano, R. Echols, J.A. Karlowsky, D.F. Sahm, Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth, *Diagnostic microbiology and infectious disease* 94(4) (2019) 321-325.
- [10] J.A. Karlowsky, M.A. Hackel, M. Tsuji, Y. Yamano, R. Echols, D.F. Sahm, In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015, *International journal of antimicrobial agents* (2018).
- [11] M.A. Hackel, M. Tsuji, Y. Yamano, R. Echols, J.A. Karlowsky, D.F. Sahm, In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study), *Antimicrobial agents and chemotherapy* 61(9) (2017).
- [12] M. Alzayer, M.F. Alghoribi, B. Alalwan, A. Alreheli, S. Aljohani, M. Bosaeed, M. Doumith, In vitro activity of cefiderocol against clinically important carbapenem non-susceptible Gram-negative bacteria from Saudi Arabia, *Journal of global antimicrobial resistance* 32 (2023) 176-180.
- [13] Y.D. Bakthavatchalam, A. Shankar, Y. Manokaran, K. Walia, B. Veeraraghavan, Can fosfomycin be an alternative therapy for infections caused by E. coli harbouring dual resistance: NDM and four-amino acid insertion in PBP3?, *JAC-antimicrobial resistance* 5(2) (2023) dlad016.
- [14] G. Bianco, M. Boattini, S. Comini, G. Banche, R. Cavallo, C. Costa, Disc Diffusion and ComASP(®) Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine, *Antibiotics (Basel, Switzerland)* 12(3) (2023).
- [15] J.E. Cañada-García, E. Ramírez de Arellano, M. Jiménez-Orellana, E. Viedma, A. Sánchez, A. Alhambra, J. Villa, A. Delgado-Iribarren, V. Bautista, N. Lara, S. García-Cobos, B. Aracil, E. Cercenado, M. Pérez-Vázquez, J. Oteo-Iglesias, Carbapenemase-Producing *Klebsiella pneumoniae* in COVID-19 Intensive Care Patients: Identification of InCL-VIM-1 Plasmid in Previously Non-Predominant Sequence Types, *Antibiotics (Basel, Switzerland)* 12(1) (2023).
- [16] I. Galani, V. Papoutsaki, I. Karaiskos, N. Moustakas, L. Galani, S. Maraki, V.E. Mavromanolaki, O. Legga, K. Fountoulis, E.D. Platsouka, P. Giannopoulou, H. Papadogeorgaki, M. Damala, E. Chinou, A. Pasxali, I.

- Deliolanis, H. Vagiakou, E. Petinaki, A. Chli, E. Vagdatli, P. Kazila, V. Papaioannou, K. Kontopoulou, A.N. Ferke, E. Moraitou, A. Antoniadou, H. Giamarellou, In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against *Acinetobacter baumannii* causing bloodstream infections in Greece, 2020-2021: a multicenter study, *European journal of clinical microbiology & infectious diseases* : official publication of the European Society of Clinical Microbiology 42(7) (2023) 843-852.
- [17] L. Devoos, A. Biguenet, J. Rousselot, M. Bour, P. Plésiat, D. Fournier, K. Jeannot, Performance of discs, sensititre EUMDROXF microplates and MTS gradient strips for the determination of the susceptibility of multidrug-resistant *Pseudomonas aeruginosa* to cefiderocol, *Clinical microbiology and infection* : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 29(5) (2023) 652.e1-652.e8.
- [18] Y.S. Huang, P.Y. Chen, P.C. Chou, J.T. Wang, In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo- β -Lactamase-Producing Enterobacteriaceae, *Microbiology spectrum* 11(3) (2023) e0056923.
- [19] B. Ihssane, E.O. Fatima, K. Aboubakr, B. Fatna, T. Mohammed, B. Pierre, H. Te-Din, N. Kaotar, First report of *Pseudomonas aeruginosa* strains co-harboring bla(NDM)-bla(VIM) and bla(VIM)-bla(IMP) metallo- β -lactamase genes in Morocco, *Journal of global antimicrobial resistance* 33 (2023) 42-43.
- [20] N. Kohira, M.A. Hackel, M. Oota, M. Takemura, F. Hu, H. Mizuno, D.F. Sahm, Y. Yamano, In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020, *Journal of global antimicrobial resistance* 32 (2023) 181-186.
- [21] C. Lasarte-Monterrubbio, P. Guijarro-Sánchez, J.C. Vázquez-Ucha, I. Alonso-García, L. Alvarez-Fraga, M. Outeda, M. Martínez-Guitián, A. Peña-Escolano, R. Maceiras, E. Lence, C. González-Bello, J. Arca-Suárez, G. Bou, A. Beceiro, Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing *Enterobacter cloacae* Complex and Characterization of Reduced Susceptibility Associated with Metallo- β -Lactamase VIM-1, *Antimicrobial agents and chemotherapy* 67(5) (2023) e0150522.
- [22] C. Le Terrier, P. Nordmann, L. Poirel, In vitro activity of aztreonam in combination with newly developed β -lactamase inhibitors against MDR Enterobacteriales and *Pseudomonas aeruginosa* producing metallo- β -lactamases, *Journal of Antimicrobial Chemotherapy* 78(1) (2022) 101-107.
- [23] S. Maraki, V.E. Mavromanolaki, D. Stafylaki, E. Scoulica, In vitro activity of newer β -lactam/ β -lactamase inhibitor combinations, cefiderocol, plazomicin and comparators against carbapenemase-producing *Klebsiella pneumoniae* isolates, *Journal of chemotherapy (Florence, Italy)* (2023) 1-5.
- [24] M. Marner, L. Kolberg, J. Horst, N. Böhringer, J. Hübner, I.D.M. Kresna, Y. Liu, U. Mettal, L. Wang, M. Meyer-Bühn, S. Mihajlovic, M. Kappler, T.F. Schäberle, U. von Both, Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant *Pseudomonas aeruginosa* Isolates from Pediatric and Adolescent Cystic Fibrosis Patients, *Microbiology spectrum* 11(1) (2023) e0443722.
- [25] M. Padovani, A. Bertelli, S. Corbellini, G. Piccinelli, F. Gurrieri, M.A. De Francesco, In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains, *Antibiotics (Basel, Switzerland)* 12(4) (2023).
- [26] P. Perez-Palacios, D. Girlich, N. Soraa, A. Lamrani, F.M.R. Maoulainine, F. Bennaoui, H. Amri, N.S. El Idrissi, M. Bouskraoui, A. Birer, A.B. Jousset, S. Oueslati, J. Raymond, T. Naas, Multidrug-resistant Enterobacteriales responsible for septicaemia in a neonatal intensive care unit in Morocco, *Journal of global antimicrobial resistance* 33 (2023) 208-217.
- [27] R.F. Potter, M.A. Wallace, C.E. Muenks, K. Alvarado, M.L. Yarbrough, C.D. Burnham, Evaluation of Variability in Interpretation of Disk Diffusion Testing for Cefiderocol Using Different Brands of Mueller-Hinton Agar, *The journal of applied laboratory medicine* 8(3) (2023) 523-534.
- [28] A. Ruedas-López, I. Alonso-García, C. Lasarte-Monterrubbio, P. Guijarro-Sánchez, E. Gato, J.C. Vázquez-Ucha, J.A. Vallejo, P.A. Fraile-Ribot, B. Fernández-Pérez, D. Velasco, J.M. Gutiérrez-Urbón, M. Oviaño, A. Beceiro, C. González-Bello, A. Oliver, J. Arca-Suárez, G. Bou, Selection of AmpC β -Lactamase Variants and Metallo- β -Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR *Pseudomonas aeruginosa* Infections, *Antimicrob Agents Chemother* 66(2) (2022) e0206721.
- [29] T. Sewunet, D. Asrat, Y. Woldeamanuel, A. Aseffa, C.G. Giske, Molecular epidemiology and antimicrobial susceptibility of *Pseudomonas* spp. and *Acinetobacter* spp. from clinical samples at Jimma medical center, Ethiopia, *Frontiers in microbiology* 13 (2022) 951857.

- [30] P.D. Tamma, Y. Bergman, E.B. Jacobs, J.H. Lee, S. Lewis, S.E. Cosgrove, P.J. Simner, Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates, *Infection control and hospital epidemiology* 44(5) (2023) 762-767.
- [31] J. Xu, H. Guo, L. Li, F. He, Molecular epidemiology and genomic insights into the transmission of carbapenem-resistant NDM-producing *Escherichia coli*, *Computational and structural biotechnology journal* 21 (2023) 847-855.
- [32] S.G. Badran, M.M. Malek, R.M. Ateya, A.H. Afifi, M.M. Magdy, E.S. Elgharabawy, Susceptibility of carbapenem-resistant Enterobacterales isolates to new antibiotics from a tertiary care hospital, Egypt: A matter of hope, *Journal of infection in developing countries* 16(12) (2022) 1852-1859.
- [33] C. Ballesté-Delpierre, Á. Ramírez, L. Muñoz, C. Longshaw, I. Roca, J. Vila, Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of *Acinetobacter baumannii* Clinical Isolates, *Antibiotics (Basel, Switzerland)* 11(2) (2022).
- [34] J.E. Cañada-García, Z. Moure, P.J. Sola-Campoy, M. Delgado-Valverde, M.E. Cano, D. Gijón, M. González, I. Gracia-Ahufinger, N. Larrosa, X. Mulet, C. Pitart, A. Rivera, G. Bou, J. Calvo, R. Cantón, J.J. González-López, L. Martínez-Martínez, F. Navarro, A. Oliver, Z.R. Palacios-Baena, Á. Pascual, G. Ruiz-Carrascoso, J. Vila, B. Aracil, M. Pérez-Vázquez, J. Oteo-Iglesias, CARB-ES-19 Multicenter Study of Carbapenemase-Producing *Klebsiella pneumoniae* and *Escherichia coli* From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3, *Front Microbiol* 13 (2022) 918362.
- [35] F.J. Candel, A. Santerre Henriksen, C. Longshaw, Y. Yamano, A. Oliver, In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection, *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 28(3) (2022) 447.e1-447.e6.
- [36] V. Di Pilato, L. Henrici De Angelis, N. Aiezza, I. Baccani, C. Niccolai, E.M. Parisio, C. Giordano, G. Camarlinghi, S. Barnini, S. Forni, L. Righi, M.T. Mechi, T. Giani, A. Antonelli, G.M. Rossolini, Resistome and virulome accretion in an NDM-1-producing ST147 sublineage of *Klebsiella pneumoniae* associated with an outbreak in Tuscany, Italy: a genotypic and phenotypic characterisation, *The Lancet. Microbe* 3(3) (2022) e224-e234.
- [37] L. Daoud, F. Al-Marzooq, C.A. Moubareck, A. Ghazawi, T. Collins, Elucidating the effect of iron acquisition systems in *Klebsiella pneumoniae* on susceptibility to the novel siderophore-cephalosporin cefiderocol, *PLoS one* 17(12) (2022) e0277946.
- [38] A. Iovleva, M.M. Mustapha, M.P. Griffith, L. Komarow, C. Luterbach, D.R. Evans, E. Cober, S.S. Richter, K. Rydell, C.A. Arias, J.T. Jacob, R.A. Salata, M.J. Satlin, D. Wong, R.A. Bonomo, D. van Duin, V.S. Cooper, D. Van Tyne, Y. Doi, Carbapenem-Resistant *Acinetobacter baumannii* in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance, *mBio* 13(2) (2022) e0275921.
- [39] J.A. Karlowsky, M.A. Hackel, M. Takemura, Y. Yamano, R. Echols, D.F. Sahm, In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019, *Antimicrobial agents and chemotherapy* 66(2) (2022) e0199021.
- [40] J.A. Karlowsky, A.J. Walkty, M.R. Baxter, H.J. Adam, P.R.S. Lagacé-Wiens, F. Schweizer, D. Bay, J.P. Lynch, 3rd, M.R. Mulvey, G.G. Zhanel, In Vitro Activity of Cefiderocol against Extensively Drug-Resistant *Pseudomonas aeruginosa*: CANWARD, 2007 to 2019, *Microbiology spectrum* 10(4) (2022) e0172422.
- [41] Karpova E.V., T. D.V., Activity of Cefiderocol and Other New Antibiotics Against Extensively Drug-Resistant *Klebsiella pneumoniae* Strains. , *Antibiotics and Chemotherapy*. 67(11) (2022) 16-21.
- [42] P. Lan, Y. Lu, Z. Chen, X. Wu, X. Hua, Y. Jiang, J. Zhou, Y. Yu, Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant *Klebsiella pneumoniae* from Bloodstream Infections in Patients with Hematologic Malignancies in China, *Microbiology spectrum* 10(2) (2022) e0008422.
- [43] C. Lasarte-Monterrubio, P.A. Fraile-Ribot, J.C. Vázquez-Ucha, G. Cabot, P. Guijarro-Sánchez, I. Alonso-García, S. Rumbo-Feal, F. Galán-Sánchez, A. Beceiro, J. Arca-Suárez, A. Oliver, G. Bou, Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam and ceftazidime/avibactam-resistant *Pseudomonas aeruginosa*, *J Antimicrob Chemother* 77(10) (2022) 2809-2815.
- [44] H.C. Mırza, G. İnce Ceviz, Comparison of in vitro activities of cefiderocol, imipenem/relebactam and other antibiotics against carbapenem-resistant *Pseudomonas aeruginosa* isolates, *Turk Hij Den Biyol Derg* 79(3) (2022) 433-442.

- [45] G. Morroni, L. Brescini, A. Antonelli, V. Di Pilato, S. Castelletti, A. Brenciani, G. D'Achille, M. Mingoia, E. Giovanetti, S. Fioriti, A. Masucci, T. Giani, A. Giacometti, G.M. Rossolini, O. Cirioni, Clinical and microbiological features of ceftolozane/tazobactam-resistant *Pseudomonas aeruginosa* isolates in a university hospital in central Italy, *Journal of global antimicrobial resistance* 30 (2022) 377-383.
- [46] G. Nayak, B. Behera, S. Mohanty, P. Kar, J. Jena, Analysis of In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Gram-Negative Bacilli by Broth Microdilution and Disk Diffusion Method: A Single-Center Study in Odisha, India, *Infection and drug resistance* 15 (2022) 5887-5897.
- [47] R.A. Ramadan, A.M. Bedawy, E.M. Negm, T.H. Hassan, D.A. Ibrahim, S.M. ElSheikh, R.M. Amer, Carbapenem-Resistant *Klebsiella pneumoniae* Among Patients with Ventilator-Associated Pneumonia: Evaluation of Antibiotic Combinations and Susceptibility to New Antibiotics, *Infection and drug resistance* 15 (2022) 3537-3548.
- [48] S. Oueslati, P. Bogaerts, L. Dortet, S. Bernabeu, H. Ben Lakhal, C. Longshaw, Y. Glupczynski, T. Naas, In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium, *Antibiotics (Basel, Switzerland)* 11(10) (2022).
- [49] D. Shortridge, J.M. Streit, R. Mendes, M. Castanheira, In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program, *Microbiology spectrum* 10(2) (2022) e0271221.
- [50] Q. Wang, L. Jin, S. Sun, Y. Yin, R. Wang, F. Chen, X. Wang, Y. Zhang, J. Hou, Y. Zhang, Z. Zhang, L. Luo, Z. Guo, Z. Li, X. Lin, L. Bi, H. Wang, Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant *Escherichia coli* before Its Approval in China: a Report from China CRE-Network, *Microbiology spectrum* (2022) e0267021.
- [51] Q. Wang, L. Jin, S. Sun, Y. Yin, R. Wang, F. Chen, X. Wang, Y. Zhang, J. Hou, Y. Zhang, Z. Zhang, L. Luo, Z. Guo, Z. Li, X. Lin, L. Bi, H. Wang, Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant *Escherichia coli* before Its Approval in China: a Report from China CRE-Network, *Microbiology spectrum* 10(3) (2022) e0267021.
- [52] C. Weber, T. Schultze, S. Göttig, J. Kessel, A. Schröder, M. Tietgen, S. Besier, T. Burbach, S. Häussler, T.A. Wichelhaus, D. Hack, V.A.J. Kempf, M. Hogardt, Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant *Pseudomonas aeruginosa* Recovered at a German University Hospital, *Microbiology spectrum* 10(5) (2022) e0169722.
- [53] P. Zalas-Więcek, K. Płachta, E. Gospodarek-Komkowska, Cefiderocol against Multi-Drug and Extensively Drug-Resistant *Escherichia coli*: An In Vitro Study in Poland, *Pathogens* 11(12) (2022).
- [54] Q. Zhang, N. Neidig, T.Y. Chu, C. Divoky, J. Carpenter, C. Lee-Hsiao, H. Threatt, R. Sultana, K. Bush, In vitro antibacterial activity of cefiderocol against recent multidrug-resistant carbapenem-nonsusceptible Enterobacterales isolates, *Diagnostic microbiology and infectious disease* 103(1) (2022) 115651.
- [55] J.C. Abdul-Mutakabbir, L. Nguyen, P.T. Maassen, K.C. Stamper, R. Kebriaei, K.S. Kaye, M. Castanheira, M.J. Rybak, In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant *Acinetobacter baumannii*, *Antimicrobial agents and chemotherapy* 65(9) (2021) e0264620.
- [56] M. Albano, M.J. Karau, A.N. Schuetz, R. Patel, Comparison of Agar Dilution to Broth Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli, *Journal of clinical microbiology* 59(1) (2020).
- [57] S.S. Bhagwat, N.J. Legakis, T. Sklidis, A. Loannidis, C. Goumenopoulos, P.R. Joshi, R. Shrivastava, S.R. Palwe, H. Periasamy, M.V. Patel, S. Chatzipanagiotou, In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals, *Diagnostic microbiology and infectious disease* 100(3) (2021) 115327.
- [58] D. Carcione, C. Siracusa, A. Sulejmani, R. Migliavacca, A. Mercato, A. Piazza, L. Principe, N. Clementi, N. Mancini, V. Leoni, J. Intra, In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against *Acinetobacter baumannii* Strains Recovered from Clinical Samples, *Antibiotics (Basel, Switzerland)* 10(11) (2021).
- [59] J.E. Choby, T. Ozturk, S.W. Satola, J.T. Jacob, D.S. Weiss, Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens, *The Lancet Infectious Diseases* 21(5) (2021) 597-598.
- [60] B. Ghebremedhin, P. Ahmad-Nejad, In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany, *Pathogens* 10(10) (2021).

- [61] A.S. Jacob, G.L. Chong, K. Lagrou, M. Depypere, S. Desmet, No in vitro activity of cefiderocol against OXA-427-producing Enterobacterales, *J Antimicrob Chemother* 76(12) (2021) 3317-3318.
- [62] B.D. Johnston, P. Thuras, S.B. Porter, C. Clabots, J.R. Johnsona, Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against extended-spectrum cephalosporin-resistant *Escherichia coli* clinical isolates (2012-20017) in relation to phylogenetic background, sequence type 131 subclones, bla(CTX-M) genotype, and coresistance, *Diagnostic microbiology and infectious disease* 100(1) (2021) 115314.
- [63] Y.L. Lee, W.C. Ko, W.S. Lee, P.L. Lu, Y.H. Chen, S.H. Cheng, M.C. Lu, C.Y. Lin, T.S. Wu, M.Y. Yen, L.S. Wang, C.P. Liu, P.L. Shao, Z.Y. Shi, Y.S. Chen, F.D. Wang, S.H. Tseng, C.N. Lin, Y.H. Chen, W.H. Sheng, C.M. Lee, H.J. Tang, P.R. Hsueh, In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020, *International journal of antimicrobial agents* 58(3) (2021) 106377.
- [64] P.Y. Liu, W.C. Ko, W.S. Lee, P.L. Lu, Y.H. Chen, S.H. Cheng, M.C. Lu, C.Y. Lin, T.S. Wu, M.Y. Yen, L.S. Wang, C.P. Liu, P.L. Shao, Y.L. Lee, Z.Y. Shi, Y.S. Chen, F.D. Wang, S.H. Tseng, C.N. Lin, Y.H. Chen, W.H. Sheng, C.M. Lee, H.J. Tang, P.R. Hsueh, In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible *Pseudomonas aeruginosa* and *Acinetobacter baumannii* isolates associated from bloodstream infection in Taiwan between 2018-2020, *Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi* (2021).
- [65] M. Biagi, A. Vialichka, M. Jurkovic, T. Wu, A. Shajee, M. Lee, S. Patel, R.E. Mendes, E. Wenzler, Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant *Stenotrophomonas maltophilia*, *Antimicrob Agents Chemother* 64(9) (2020).
- [66] M. Delgado-Valverde, M.D.C. Conejo, L. Serrano, F. Fernández-Cuenca, Á. Pascual, Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia*, *J Antimicrob Chemother* 75(7) (2020) 1840-1849.
- [67] A.R. Golden, H.J. Adam, M. Baxter, A. Walkty, P. Lagacé-Wiens, J.A. Karlowsky, G.G. Zhanel, In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units, *Diagnostic microbiology and infectious disease* 97(1) (2020) 115012.
- [68] A. Iregui, Z. Khan, D. Landman, J. Quale, Activity of Cefiderocol Against Enterobacterales, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* Endemic to Medical Centers in New York City, *Microbial drug resistance (Larchmont, N.Y.)* 26(7) (2020) 722-726.
- [69] B.D. Johnston, P. Thuras, S.B. Porter, M. Anacker, B. VonBank, P. Snippes Vagnone, M. Witwer, M. Castanheira, J.R. Johnson, Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant *Escherichia coli* Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region, *Antimicrobial agents and chemotherapy* 64(10) (2020).
- [70] M. Kresken, M. Korte-Berwanger, S.G. Gatermann, Y. Pfeifer, N. Pfennigwerth, H. Seifert, G. Werner, In vitro activity of cefiderocol against aerobic Gram-negative bacterial pathogens from Germany, *International journal of antimicrobial agents* 56(4) (2020) 106128.
- [71] C. Longshaw, D. Manissero, M. Tsuji, R. Echols, Y. Yamano, In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe, *JAC-antimicrobial resistance* 2(3) (2020).
- [72] M.A. Hackel, M. Tsuji, Y. Yamano, R. Echols, J.A. Karlowsky, D.F. Sahm, In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016, *Antimicrobial agents and chemotherapy* 62(2) (2018).
- [73] S. Mushtaq, Z. Sadouki, A. Vickers, D.M. Livermore, N. Woodford, In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria, *Antimicrobial agents and chemotherapy* 64(12) (2020).
- [74] K.V.I. Rolston, B. Gerges, S. Shelburne, S.L. Aitken, I. Raad, R.A. Prince, Activity of Cefiderocol and Comparators against Isolates from Cancer Patients, *Antimicrobial agents and chemotherapy* 64(5) (2020).
- [75] D.A. Talan, S.S. Takhar, A. Krishnadasan, W.R. Mower, D.J. Pallin, M. Garg, J. Femling, R.E. Rothman, J.C. Moore, A.E. Jones, F. Lovecchio, J. Jui, M.T. Steele, A.M. Stubbs, W.K. Chiang, G.J. Moran, Emergence of

- Extended-Spectrum β -Lactamase Urinary Tract Infections Among Hospitalized Emergency Department Patients in the United States, *Annals of emergency medicine* 77(1) (2021) 32-43.
- [76] V. Trebosc, B. Schellhorn, J. Schill, V. Lucchini, J. Bühler, M. Bourotte, J.J. Butcher, M. Gitzinger, S. Lociuero, C. Kemmer, G.E. Dale, In vitro activity of rifabutin against 293 contemporary carbapenem-resistant *Acinetobacter baumannii* clinical isolates and characterization of rifabutin mode of action and resistance mechanisms, *J Antimicrob Chemother* (2020).
- [77] O. Xie, K. Cisera, L. Taylor, C. Hughes, B. Rogers, Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible *Escherichia coli* bloodstream infection, *Annals of clinical microbiology and antimicrobials* 19(1) (2020) 57.
- [78] S.C. Hsueh, Y.J. Lee, Y.T. Huang, C.H. Liao, M. Tsuji, P.R. Hsueh, In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, and *Stenotrophomonas maltophilia*, all associated with bloodstream infections in Taiwan, *The Journal of antimicrobial chemotherapy* 74(2) (2019) 380-386.
- [79] M.R. Jacobs, A.M. Abdelhamed, C.E. Good, D.D. Rhoads, K.M. Hujer, A.M. Hujer, T.N. Domitrovic, S.D. Rudin, S.S. Richter, D. van Duin, B.N. Kreiswirth, C. Greco, D.E. Fouts, R.A. Bonomo, ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β -Lactamases and Carbapenemases, *Antimicrobial agents and chemotherapy* 63(1) (2019).
- [80] K.M. Kazmierczak, M. Tsuji, M.G. Wise, M. Hackel, Y. Yamano, R. Echols, D.F. Sahm, In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo- β -lactamase-producing isolates (SIDERO-WT-2014 Study), *International journal of antimicrobial agents* 53(2) (2019) 177-184.
- [81] M.E. Falagas, T. Skolidis, K.Z. Vardakas, N.J. Legakis, Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals, *The Journal of antimicrobial chemotherapy* 72(6) (2017) 1704-1708.
- [82] S. Kanazawa, T. Sato, N. Kohira, T. Ito-Horiyama, M. Tsuji, Y. Yamano, Susceptibility of Imipenem-Susceptible but Meropenem-Resistant bla(IMP-6)-Carrying Enterobacteriaceae to Various Antibacterials, Including the Siderophore Cephalosporin Cefiderocol, *Antimicrobial agents and chemotherapy* 61(7) (2017).
- [83] A. Ito, N. Kohira, S.K. Bouchillon, J. West, S. Rittenhouse, H.S. Sader, P.R. Rhomberg, R.N. Jones, H. Yoshizawa, R. Nakamura, M. Tsuji, Y. Yamano, In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria, *J Antimicrob Chemother* 71(3) (2016) 670-7.
- [84] N. Kohira, J. West, A. Ito, T. Ito-Horiyama, R. Nakamura, T. Sato, S. Rittenhouse, M. Tsuji, Y. Yamano, In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains, *Antimicrobial agents and chemotherapy* 60(2) (2016) 729-34.
- [85] P. Thelen, A.S. Henriksen, C. Longshaw, Y. Yamano, B. Caldwell, A. Hamprecht, In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany, *Journal of global antimicrobial resistance* 28 (2022) 12-17.
- [86] S. Stracquadanio, E. Torti, C. Longshaw, A.S. Henriksen, S. Stefani, In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy, *Journal of global antimicrobial resistance* 25 (2021) 390-398.
- [87] E. Cercenado, L. Cardenoso, R. Penin, C. Longshaw, A.S. Henriksen, A. Pascual, In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Spain, *Journal of global antimicrobial resistance* 26 (2021) 292-300.
- [88] T. Naas, G. Lina, A. Santerre Henriksen, C. Longshaw, F. Jehl, In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in France, *JAC-antimicrobial resistance* 3(2) (2021) dlab081.
- [89] V. Gant, A. Hussain, M. Bain, C. Longshaw, A.S. Henriksen, In vitro activity of cefiderocol and comparators against Gram-negative bacterial isolates from a series of surveillance studies in England: 2014-2018, *Journal of global antimicrobial resistance* 27 (2021) 1-11.
- [90] T. Sato, A. Ito, Y. Ishioka, S. Matsumoto, M. Rokushima, K.M. Kazmierczak, M. Hackel, D.F. Sahm, Y. Yamano, *Escherichia coli* strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study, *JAC-antimicrobial resistance* 2(3) (2020) dlaa081.

[91] N. Kohira, M.A. Hackel, Y. Ishioka, M. Kuroiwa, D.F. Sahm, T. Sato, H. Maki, Y. Yamano, Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014), *Journal of global antimicrobial resistance* 22 (2020) 738-741.